
==== Front
J Transl Med
J Transl Med
Journal of Translational Medicine
1479-5876
BioMed Central London

5587
10.1186/s12967-024-05587-9
Review
Nutraceuticals and pharmacological to balance the transitional microbiome to extend immunity during COVID-19 and other viral infections
http://orcid.org/0000-0002-0902-5461
Kaushal Anju anjukaushal186@hotmail.com
anjukaushal186@gmail.com

Auckland, New Zealand
18 9 2024
18 9 2024
2024
22 84718 12 2023
8 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Scope

The underlying medical conditions and gut dysbiosis is known to influence COVID-19 severity in high-risk patients. The current review proposed the optimal usage of nutraceuticals & pharmacological interventions can help regulate the protective immune response and balance the regulatory functionality of gut microbiota.

Summary

Many studies have revealed that the probiotic interventions viz., Lactobacillus rhamnosus, L. plantarum & other bacterial spp. reduce IFNγ & TNF-α and increase IL-4 & IL-10 secretions to control the immunostimulatory effects in upper respiratory tract infection. Dietary fibres utilized by beneficial microbiota and microbial metabolites can control the NF-kB regulation. Vitamin C halts the propagation of pathogens and vitamin D and A modulate the GM. Selenium and Flavonoids also control the redox regulations. Interferon therapy can antagonize the viral replications, while corticosteroids may reduce the death rates. BCG vaccine reprograms the monocytes to build trained immunity. Bifidobacterium and related microbes were found to increase the vaccine efficacy. Vaccines against COVID-19 and season flu also boost the immunity profile for robust protection. Over all, the collective effects of these therapeutics could help increase the opportunities for faster recovery from infectious diseases.

Conclusion

The nutraceutical supplements and pharmacological medicines mediate the modulatory functionalities among beneficial microbes of gut, which in turn eliminate pathogens, harmonize the activity of immune cells to secrete essential regulatory molecular receptors and adaptor proteins establishing the homeostasis in the body organs through essential microbiome. Therefore, the implementation of this methodology could control the severity events during clinical sickness and reduce the mortalities.

Keywords

COVID-19
Gut microbiota
Dietary fibres
Vaccines
Antibiotics
Vitamins
issue-copyright-statement© BioMed Central Ltd., part of Springer Nature 2024
==== Body
pmcIntroduction

The pathophysiological conditions and hyperinflammatory immune responses are the main concerning areas in terms of exploring the COVID-19 severity. The pre-existing comorbid conditions such as, diabetes mellitus, rheumatoid arthritis, angioimmunoblastic lymphadenopathy with dysproteinemia, cardiovascular diseases, neurological disorders, other inflammatory disorders and underlying conditions due to misuse of antibiotics etc., are known to increase the susceptibility to dysbiosis, resulting in prolonged hospitalization in COVID-19 patients escalating mortality rates [1, 2]. Microbiome research has attained great attention in the past decade because of its beneficial attributes. Bacterial species like, Coprobacillus, Clostridium, Firmicutes, Bacteroides, Proteobacteria and Actinobacteria influence the SARS-CoV-2 infection subsequently increase the disease severity. The altered gut microbiota due to COVID-19 may flare up the early induced ‘Cytokine Storm’ elevating the levels of IL-1β, IL-6, tumour necrosis factor-α (TNF-α), monocyte chemoattractant protein-1 (MCP-1), and macrophage inflammatory protein-1α (MIP-1α) and Chemokine C–C motif ligand 3 (CCL3) [1, 3, 4]. Additionally, the psychological wellbeing of patients can also be impacted via. crosstalk between gut and brain during illness and dysbiosis [5].

Interferons also provide immune modulatory response to suppress the early viral infection and regulate the α-defensin [6, 7]. Similarly, corticosteroids (glucocorticoids) suppress the initial infection and have found to control the 62% death rate, but eventually reduced to 28% in patients on ventilators [8, 9]. Effectiveness of vaccines are also described in literature to attenuate the gut microbiome restoring the essential commensals that activate NOD2 sensors and IgA production contribute to restore the intestinal barrier function [2, 10].

Post acute COVID-19 syndrome is described as the chronic form of COVID-19 could last for 6 months or years. The mood disorders and autoimmune dysfunctions manifested as a consequence of infectious disease, genetic, environmental and socioeconomic problems, are the predisposing factors towards developing chronic fatigue syndrome. PACS is likely to be contexed with chronic distress and brain fog with cognitive impairment. The post infection fatigue syndrome has also been documented in case of influenza, dengue, Epstein-Barr virus, enteroviruses, human parvovirus and protozoan infections [5, 11]. Lack of important nutrients e.g., vitamin C, B, D, sodium and magnesium, zinc, folic acid etc. may worsen the illness [5].

The viruses and bacteriophages distribute the essential regulatory genes required for vital activities and genetic make-up of microflora. Antibiotics associated dysbiosis occurred can be repaired with the help of appropriate probiotics eventually confer the better performance of microbiome, hence, mitigating the risks of poor disease prognosis. WHO had already provided the plans for food and nutrition to people who were supposed to go through the self-quarantine during COVID-19 outbreak in order to strengthen the immunity, irrespective of their acquired disease status. Following the diet regimens including dietary fibres, omega-3-polyunsaturated fatty acids (ω-PUFA), polyphenols, vitamin A, C, D etc. along with probiotics, could help offset the ‘cytokine storm’ formation. The bioactive compounds, however, must be optimally evaluated and employed for the management of viral diseases and associated chronic fatigue syndrome. The nutraceutical supplements, pharmacological therapeutics and their interactions with microbiota is supposed to unveil the positive immunological activities could impact the disease outcomes [5, 12–17].

This review emphasizes the values of optimal use of nutraceuticals (active compounds) and pharmacological sources to moderate the immune response by controlling the hyperactivated macrophages/monocytes to halt the excessive production of cytokines and chemokines. Consequently, these events help release the molecular adaptors, which program the chromatin functionality via histones at transcriptional level to impact the post translational modifications during cell differentiation. Undoubtedly, this approach would be a step forward for the earlier & faster recovery of both asymptomatic and symptomatic patients.

Effects of nutraceuticals

Probiotics

Food and Agriculture Organization (FAO) and World Health Organization (WHO) have defined ‘Probiotics’ as microbes confer the health benefits to the host [18–20]. Probiotics (Lactobacillus, Bifidobacterium, and Saccharomyces spp.) and prebiotics (non-digestible food ingredients) attenuate the microbiota and increase GM’s survival [20, 21]. By preserving the gut microflora through bioactive food supplements increase the capability of immune cells to control cytokines’ release, TNF-α and activate the reactive oxygen species (ROS) to establish optimal anti-viral state [21]. The probiotic supplements have been experimented on ARDS and pneumonia in COVID-19 patients on ventilation has shown significant improvement [1]. L. rhamnosus GG is safer and efficacious in preventing viral associated pneumonia (VAP) in high-risk ICU population [22, 23]. However, there is still lack of sufficient peer reviewed information on the probiotic supplements in controlling the ventilation associated pneumonia [24].

The cellular immunity is increased using Enterococcus faecium NCIMB 10415 that provokes IL-6 and IL-8 secretion to fight against the TGEV infection in young piglets. European food safety authority has developed a guidance to use E. faecium in dose dependent manner in animals [25]. Certain Bacteroides spp. and Akkermansia muciniphila are known to utilize mucin polyLacNAc via O-glycanases & glycoside hydrolases for their continual survival. However, the excessive usage of mucin could allow pathogens to grow faster to raise the alarm for inflammatory bowel disease (IBD) and even colorectal cancer [26]. Table 1 and Fig. 1 represent the comprehensive details on the characteristics and molecular mechanisms of microbiota. The bioactive food supplements, prebiotics, and synbiotics can be utilized as adjunctive therapeutics, attributed to control the secondary infections too [27]. The legitimate safety and efficacy of probiotics for the regulatory point of view is yet to be investigated against infectious diseases.Table 1 Immunomodulatory and pathological implications to fight against diseases using favourable microbes and nutraceuticals (dietary fibres, vitamins, polyunsaturated fatty acids and flavonoids)

Relevant features	Modulatory/pathological factors	References	
Bioactive supplements (prebiotics, probiotics & synbiotics)	
 Bioactive food supplements with probiotics increase the survival of commensals

 Restore microflora diversity

	TLR modulation, balance the immune response to confer viral clearance, boost vitamin's absorption

↓Allergic reactions & pulmonary symptoms

↑ Lung’s protection, TLR modulation, viral clearance & vit. absorption

	[2, 5, 18, 19, 22–25, 27, 86–94]	
 Lactobacillus, Bifidobacteria, and Saccharomyces spp. are the mainly used as probiotics	Can control the ventilation associated pneumonia and the cytokine storm with ARDS in COVID-19 patients	
 BP-38 catabolic activator from Paenibacillus spp.	Suppress ACE-2 function (Mice model)	
 E. faecium can treat intestinal cells	Stimulate IL-6 and IL-8 to raise cellular immunity against TGEV infection	
 Capsular polysaccharide A-Bacteroides fragilis	Induce IFNβ in-vitro and DCs in lamina propria of colon to resist against viral infection	
 Parabacteroides, Bacteroides, and Lachnospiraceae families	Help synthesize SCFAs to modulate the immune cells, balance the innate response, and maintain the integrity of mucosa	
 Lactobacilli and Bifidobacterial spp.	Used in antibiotic associated diarrhoea	
 Blautia wexlerae and Bifidobacterium longum with other bacterial spp. were negatively associated with post-acute covid syndrome PACS at 6 months	Microbiota modulation may assist in early and safe recovery minimizing the risk of developing PACS	
 Probiotics formulated (450 billion bacteria) used specific strains of Bifidobacterium breve DSM24732, Streptococcus thermophilus DSM 24731, Bifidobacterium infantis DSM 24737, Bifidobacterium longum DSM 24736, Lactobacillus acidophilus DSM 24735, Lactobacillus paracasei DSM 24733, Lactobacillus plantarum DSM 24730, Lactobacillus delbrueckii subsp.   bulgaricus DSM 24734	Patients with familial Mediterranean fever FMF (inter-critical period) were observed with improved symptoms	
 L. plantarum DR7	↓ IFNγ & TNF-α concentration, and ↑ IL-4 and IL-10 in young adults with upper respiratory infection	
 Lactobacillus casei DN-114001 used in clinical controlled trial	↓ episodes of upper respiratory tract infections within 3 months	
 Lactobacillus rhamnosus GG	↓ hospitalization, control the imbalance in microbiota richness induced by antibiotics and ↑ microbiota diversity	
Dietary fibres (DFs)	
 DFs help maintain the gut microbiome composition	hsCRP, IL-6, TNF-α induction is reduced, control the inflammation	[2, 5, 12, 13, 28–31, 36]	
 Phenolic compounds of DFs influence the diversified growth of gut microbiota with Lactobacillus, Bifidobacterium, Akkermansia and Faecalobacterium	Inhibit Helicobacter pylori and Staphylococcus spp.	
SCFAs synthesized from Bifidobacterium spp. and Lactobacillus spp.	↓ growth of pathogen like Clostridium spp.	
 SCFA related GPCRs activation, increase the signaling of anti-inflammatory cascade	↑ IL-12 inhibition and IL-10 upregulation	
 Exopolysaccharides- homopolymers-cellulose, levan, curdlan, dextran	↓ TNF-α & IL-1 and NF-kB hyper-production	
 Heteropolymers- xanthan, gellan, galactan, kefiran are produced by Lactococcus lactis, Lactobacillus spp., Streptococcus thermophilus, Weissella confusa, Leuconostoc spp., and Pediococcus spp.	Modulate CD8+ and Tc17 cells and↑ anti-inflammatory properties	
 Enzymes (oxidoreductase, transferases, hydrolases, lyases, isomerases, ligases) secretion from Bacillus subtilis, Bacillus licheniformis, Aspergillus niger, Aspergillus oryzea and Lactobacillus lactis	Immunomodulatory, antitumor, antimutagenic, anti-oxidant, anti-inflammatory, anti-hypertensive, antibacterial and antiviral, cholesterol lowering, anti-IBD properties	
 Cell wall components (Peptidoglycan-Teichoic acid and Lipoteichoic acid) especially from gram+ ve bacteria e.g., Lactobacillus spp.	Promote physiological, biochemical and regulatory properties	
 Cell Free supernatant and bacterial lysate from Lactobacillus spp. and Bifidobacteriums pp.	Immunostimulatory and safe to human health except biogenic amino acids and d-lactis acid	
Vitamins	
 Vitamin C (l-ascorbic acid-2-glucoside)	Neutralise the oxidative stress, apoptotic response, decrease the cellular viability in H. pylori

Also inhibit HSV, polio, and influenza

	[5, 40, 42–46]	
 Vitamin D&E	Bifidobacterium, Lactobacillus, Akkermansia, Roseburia to get modulated. Could reduce Firmicutes/Bacteroides (F/B) ratio, if used inappropriately	
 Vitamin E with Selenium and retinoic acid	Ameliorate mucosal inflammation, ↑ Bacteroidetes and ↓  Firmicutes (mice model). Inhibit Norovirus replication, but ↑ Lactobacillus spp. abundance	
 Vitamin A exhibits adjuvant properties	Retinoic acid vit A can cause the hepatotoxicity, if used inappropriately	
 Vitamin D	Immunomodulatory/and anti-inflammatory effects on immune cells

↓ hospitalization potentially while maintaining the adequate level (> 20 to < 50 ug/ml). Administered at higher doses can reduce ICU admissions

	
 Vitamin K deficiency	Poor prognosis of COVID-19. Moderate level of Vit K suppresses the co-infections with COVID-19 with increased use of antibiotics	
Essential trace minerals—selenium & zinc	
 Selenium increases the beneficial microbes such as, Akkermansia, Lactobacillus, and Faecalbacterium and depletes the deleterious microbes like Dorea and Mucispirillum	Gut microbiota to secrete SCFAs to control the inflammatory bowel disease (IBD) and colitis, by decreasing the GM impairment

Regulates the redox state

	[29, 35, 47–50]	
 Zn is essential for the normal functioning of the immune system	Combines with ionophore pyrithione help inhibit the SARSCoV-1, polio and influenza replication

Inhibit RNA synthesis by inhibiting the activity of enzyme RdRp

	
 Zn & Selenium supplementation at non-toxic level	Binds S100 protein fecal-calprotectin exert anti-microbial effects against C. difficile

Strengthen the immune system

	
Polyunsaturated fatty acids	
 ω-3-PUFA influence the immune cells activation	Metabolize into prostaglandins, leukotrienes, thromboxanes, maresins, protectins and resolvins used by immune cells

SCFA & butyrate producing microbial  growth is increased with Bifidobacterium, Lachnospira, Roseburia, and Lactobacillus

↓ risk of hospitalization 12–20% in COVID-19 patients

Downregulate the IL-2 driven CD4+ and CD8+ T-cell activation

Indirect suppression of Th1 cells, increase the cross regulatory function of Th2 producing anti-inflammatory effects

	[14–16, 51, 77]	
Flavonoids	
 Flavonoids help treating the viral infections	↑ Treg and T17 cells to inhibit the pathogens	[17, 52]	
 Increase Bifidobacterium spp. and Lactobacillus spp.	Suppress the TLR4, 1kB phosphorylation to decrease the nuclear translocation of NF-kB	
 Halt the growth of Clostridium spp., Helicobacter pylori, Escherichia coli, and Salmonella typhimurium	Antioxidant properties of flavonoids protect against the cardiovascular, metabolic and neurodegenerative disorders	

Fig. 1 Illustration of the molecular mechanisms developed during administration of pharmaceutical interventions and nutraceutical supplements [2, 5, 16, 21, 25, 27, 28, 32, 33, 36–39, 66, 67, 69, 73, 74, 78, 83, 84, 95]. Bacteroides via glycolysis to produce SCFAs & other acetates are utilized by other commensals through TCA giving innate protection to myeloid cells. SCFAs regulate IL-10 and halt IL-17A, & via Th1 activating ROS to clear pathogens. Influenza vaccine regulates TLR5. Vit D via VDR activates the cathelicidin, α-defensin and AMP synthesis against pathogens. Microbiota secreted 3-IPA acts as an allosteric inhibitor to tryptophan of Mycobacterium tuberculosis & non-mycobacterial spp. ω-3 PUFAs indirectly activate Th2 cells to regulate IL-4, IL-5, IL-10, IL-13 via STAT-6 pathway, by repressing Th1. IFN+ Ribavirin regulates IFN & change IFN agonist e.g., ORF 3b and ORF 6. MAMPs and PRRs regulate the CD4+ cells. Deactivation of IFNA2 is correlated with seroconversion. BCG vaccine reprograms the monocytes through histone alterations inhibiting HADCs activity to control the metabolic and epigenetic disorders building trained immunity. Bacteroides utilized mucin for longer survival and regulate pro-IL-18 & ILC3. Enterococcus faecium to stimulate IL-6 & IL-8 to fight against TGEV

Dietary fibres (DFs)/prebiotics

Dietary fibres (DFs) are the plant derived foods utilized by microbes to yield the beneficial byproducts like SCFAs. These metabolites activate the anti-inflammatory cascade through G-proteins coupled receptors (GPRs) that repress IL-2 and upregulate IL-10 in monocytes. SCFAs also halt TNF-α, IL-1, but regulate nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) [28]. The consumption of DFs (5 g/day) reduces the level of C-reactive protein (hsCRP), IL-6, TNF-α etc. Therefore, SCFAs promote migration of immune cells near inflammatory sites to clear the pathogens via. ROS to lower the systemic and gut inflammation (Table 1) [28–30]. The enrichment of diversified beneficial bacteria such as, Bifidobacterium spp. and Lactobacillus spp. inhibit the growth of detrimental pathogens like Clostridium spp. The phenolic compounds rich DFs promote the propagation of Lactobacillus, Bifidobacterium, Akkermansia, and Faecalibacterium, but suppress the growth of Helicobacter Pylori and Staphylococcus spp. [31].

Postbiotics

The postbiotics are the metabolic byproducts of commensals vitally used for many physiological and metabolic functions to maintain the homeostasis effectively [13]. The SCFAs, mainly constitute acetate, propionate and butyrate, are recognized by GPRs-GPR 41 & 43. The GPR 41 and GPR 109 in adipose tissues metabolize into acetyl CoA regulating TCA cycle and cell function [32]. The colonic low pH, and serum lipid profile are also restored by SCFAs. Overall, effective use of SCFAs strengthen the immune system fighting with pulmonary diseases, hence, reducing the mortalities [28, 33, 34]. SCFAs also increase the TjP integrity against pathogens invasion [35].

SCFAs inhibit the activity of histone deacetylase (HDAC) to control the process of deacetylation and histone crotonylation involving in the post-translational modification facilitating the gene changes, hence, regulate the chromatin architecture critical for epigenetic modification during cell cycle and differentiation [36]. The indole and IPA also modulate the cells to produce antibodies (Fig. 1). Exopolysaccharides-homopolymers (cellulose, levan, curdlan, and dextran) and heteropolymers (xanthan, galactan, kefiran) are the biproducts of Lactococcus spp., Streptococcus spp., Leuconostoc spp., that downregulate the IL-1 and TNF-α and upregulate CD8+ and T17 cells (Table 1). Various enzymes like, oxidoreductase, transferase, hydrolases, lyases, isomerases being secreted from Bacillus subtilis, Bacillus licheniformis, Aspergillus niger, and Aspergillus oryzae. Lactobacillus lactis provides every possible aspect of maintaining the homeostasis through anti-inflammatory, antitumor, anti-cholesterol and antioxidant response (Table 1). Physiological and metabolic pathways are also regulated using cell wall components and cell free components of Lactobacillus spp. [12, 13].

The mucin degrading bacteria target the polyLacNAc structures with in oligosaccharide side chains in both humans and animals. These O-glycanase enzymes are the glycoside hydrolase16 (GH16) family indicating their role in mucin break down. This administers the advanced knowledge of mechanisms of mucin breakdown by normal microbiota, could provide a research tool to explore O-glycan for intestinal diseases. Bacteroides spp. and Akkermansia muciniphila utilize mucins for their long -term survival. However, the excessive usage of mucin could allow pathogens to grow faster raise the alarm for inflammatory bowel disease (IBD) and even colorectal cancer [26].

The bioactive food supplements, prebiotics, and synbiotics can be utilized as adjunctive therapeutics, as these modulate DCs and regulate IFNs. Besides, repairing the altered microbiota to boost immunity against SARSCoV-2 infection, it also assists in controlling the secondary viral and bacterial infections [27, 37]. Pathological and modulatory events using probiotics and pre and post biotics are explained in Tables 1 and 2.Table 2 Pharmacological interventions to influence the immune modulatory/or pathological events via. microbiota

Relevant characteristics	Immune modulatory/pathological events through microbiota	References	
Interferons	
 IFN-α and IFN-β harness anti-SARS and anti-MERS properties

 IFN-β with ribavirin

 IFN effects on Calu3 2B4 cells

 Interferon tau

	Immune-modulatory effects on innate immune system

Protect susceptible and severely ill patients

Could suppress the virus replication & transmission

↓ SARSCoV-2 replication. Induce the STAT-1 phosphoryaltion, ORF3b and ORF6 changes couldn’t antagonize IFN

Changes GM and IL-17, protect against influenza (Mice)

↓ Firmicutes and ↑Bacteroides in jejunum and ileum

	[7, 53, 54, 56, 57, 79]	
Corticosteroids	
 Corticosteroids (DEX) are used in asthma, allergies and autoimmune disorders

 GM gets altered using DEX, retaining Bifidobacterium and Lactobacillus (For anti-inflammatory effects- mice model)

	Influence physiological functions, reduce massive lung damage, activate transcription factor- TF to regulate NF-kB and AP-1

to decrease proinflammatory cytokine production

Synthetic glucocorticoids methylprednisolone administration in ARDS COVID-19 patients could decrease the risk of death by 62%

Long-term use—cause lipid accumulation & upregulation of GC receptor to cause circadian rhythm disorder

	[59–63, 80]	
Antibiotics	
 Antibiotics treatment to combat the secondary infection during COVID-19 could kill gram −ve/+ve gut microflora

 Broad spectrum antibiotic perturbation

	Alter gut microbiota and cause gut dysbiosis, dysregulation of DCs activation

↑ tissue pathology by CX3CR1 + in mononuclear cells

↓ Bacteroidetes, Increase the circulatory inflammatory signatures

↓ expression of IFN-γI, MHC-I, CD40 during the early viral infection and ↓ modulated GM

↑ secretion of IFNγ, IL-6, CCL-2 and ↓ Treg cells, cause permanent dysbiosis

	[64, 81, 82, 90]	
Vaccines	
 BCG vaccine (live-attenuated) produces heterologous immune response against Tuberculosis and other infections

 Bifidobacterium adolescentis immunomodulates the response

 Bifidobacterium adolescentis, Butyricimonas virosa, Adlercreutzia equolifaciens and Asaccharobacter celatus

 Ruminococcus torques, Eubacterium ventriosum and Streptococcus salvarius

 Prevotella copri and Megamonas species

 Prevotella copri

 Megamonas funiformis, Megamonas hypermegale

	Modulates the immune response against the metabolic and epigenetic disorders

Flagellin and peptidoglycan are adjuvant in nature

TLR-4 activated by LPS to ↑ adaptive response

TLR5 are sourced from microflora activate the response against influenza and polio vaccine

↑ response against CoronaVac vaccine, but single dose with BNT162b2 generated a ↓ level of neutralizing titre

Bifidobacteria potentiates the carbohydrate driven immunogenic effects for ↑ Ab production

Beneficial effects on NAb immune response generated using CoronaVac vaccine, also affect the body weight and BMI in CoronaVac vaccine

↑ response to vaccine

↓ adverse effect and ↑ anti-inflammatory

Linked with farnesoid X receptor signaling via modulating bile acid metabolism

Ferment glucose into acetate and propionate to maintain homeostasis, regulate T17 helper cells

	[66–72]	

Vitamins

Vitamins have adjuvant properties and restore health beneficial bacteria e.g., Bifidobacterium, Lactobacillus, Akkermansia, and Roseburia. The micronutrients execute anti-oxidant function to attenuate immunostimulatory inflammation. Vitamins/antioxidants may alter the circulatory ROS and levels of antioxidant enzymes such as, superoxide dismutase SOD, catalases, peroxiredoxins-PRXs, glutathione peroxidases-GPXs etc., which follow the ascorbate glutathione pathway. Vit. C, D and E can reduce the Firmicutes and Bacteroides (F/B) ratio. Vitamin K deficiency could lead to the poor prognosis of COVID-19. Vit. D via VDR receptors, induces the antimicrobial cathelicidin in macrophages and synthesis of α-defensin & antimicrobial peptides (AMPs), and reduce the production of inflammatory cytokines (Table 1 and Fig. 1) [5, 38]. The interventional studies have shown that vit. D alters the microbiota composition by increasing the beneficial microbes viz., Ruminococcus, Akkermansia, Faecalibacterium, Lactococcus, and Coprococcus, while decreasing Firmicutes. Hence, maintaining the appropriate level of vitamin D helps balancing the microbiota [39]. Vitamin D is administered in higher dose significantly reduce the risk of ICU admissions in COVID-19 cases [40]. The hospitalized patients (84%), with COVID-19 were reported to deficient in vit. D [25 (OH) D], were associated with higher D-dimer level, could be considered as a factor for disease prognosis. Maintaining the adequate level of vit. D (> 20 to < 50 ug/ml) could reduce the direct hospitalizations, non-invasive ventilation support and ICU admissions [41, 42].

Vitamin C could provide the non-specific protection against the respiratory infections with Mycobacterium tuberculosis, Pseudomonas aeruginosa, heamolytic Streptococci, Staphylococcus aureus MRSA, E. faecalis, E. coli O 157: H7, Klebsiella pneumoniae and Proteus mirabilis. Supplementation with vitamin C, D and vitamin E in the nutritional sources facilitate the growth of Bifidobacterium, Lactobacillus, and Roseburia to control the lower ratio of Firmicutes/Bacteroides, consequently the beneficial gut microbes’ abundance is enhanced [21, 28]. l-ascorbic acid-2-glucoside, a form of vitamin C could neutralize/or counteract with oxidative stress, apoptotic responses, and decreased cellular viability caused by Helicobacter pylori. It also holds the anti-Campylobacteriosis and anti-Salmonellosis properties. An oxidized form of vit. C dehydroascorbic acid could inhibit the replication of herpes simplex virus type 1, polio virus type 1 and influenza virus type A and so as to reduce the parasite count too in case of Plasmodium and Trypanosoma. Vitamin D is associated with inhibition of Hsp90-mediated proteostasis which governs morphogenesis, by repressing the cyclic AMP-protein kinase A in Candida albicans [30, 43].

Vitamins also modulate the health beneficial bacteria e.g., Bifidobacterium, Lactobacillus, Akkermansia, and Roseburia. Vitamin D and E can control the Firmicutes and Bacteroides (F/B) ratio (Fig. 2, Table 1). Vitamin E with selenium and retinoic acid induces the restoration of gut microflora to increase Bacteroidetes and decrease Firmicutes (mice model), thus ameliorating the mucosal inflammations [44]. Adjuvant nature of vit. A inhibits norovirus replication and increases Lactobacilli abundance [45]. Bile acids and microbiota contribute to optimize the level of vitamin K [46]. But vitamin K deficiency could lead to the poor prognosis of COVID-19.Fig. 2 Properties of Nutraceuticals and Pharmacological interventions to regulate the protective immune activities in alveolar and gut cell linings. A probable modulatory effect of probiotics with supplements to build ILC 3 homeostasis in gut and the functional integrity of the other body organs [2, 20, 29–32, 36]

Selenium, zinc and ω-3 PUFAs

Selenium (Se) is an essential trace mineral required for selenocysteine synthesis, catalysed by glutathione peroxidase (GPxs), thus, having a significant role in redox state regulation. It depletes the deleterious microbes like Dorea and Mucispirillum, but increase the beneficial microbes like Akkermansia, Lactobacillus, and Faecalibacterium [29, 47, 48].

Zinc (Zn) and Selenium help strengthen the immune system. Zn controls the level of inflammatory mediators, activity of O2 and N2, which destroy the host tissues. Ionophore pyrithione blocks SARSCoV-1, polio and influenza replication [49]. Zn-pyrithione could halt the growth of deleterious microbes interfering with copper flux and inhibit the ionophore loading in nucleus. Zn also showed a calprotectin-mediated antimicrobial effects in C. difficile [50].

Omega-3 polyunsaturated fatty acids (ω-3 PUFAs) and Omega-6 fatty acids intake could reduce 12–21% risk of COVID-19, hence, reduce hospitalization and ventilation. However, in critical cases the higher level of fatty acids has resulted in the formation of ‘cytokine storm’ in lungs increasing the mortality. Therefore, it is imperative to investigate the risk of dose level with Omega 3 fatty acids [15]. ω-3 PUFAs augment the production of SCFAs through Bifidobacterium, Lachnospira, Roseburia, and Lactobacillus [14, 51].

Flavonoids

Flavonoid compounds have antioxidant properties to provide protective effects on broad range of disorders viz., cardiovascular, metabolic and neurodegenerative. Antioxidant compounds increase the growth of symbiotic microbes Bifidobacterium spp. and Lactobacillus spp., while hindering the growth of Clostridium spp., Helicobacter pylori, Escherichia coli, and Salmonella typhimurium [17, 52]. Flavonoids and microbiome interactions could be helpful in the treatment of viral infections. Flavonoids increase Treg and T17 cells and inhibit the pathogens to propagate. They also suppress the TLR4, reduce the 1kB phosphorylation to decrease the nuclear translocation of NF-kB [28, 36]. A microbial phenolic acid, Desaminotyrosine (DAT), is secreted by Clostridium orbiscindens helping rescued the antibiotic treated influenza-infected mice, via 1 IFN signaling increment stopping the lung pathology [53].

Pharmacological interventions

Interferons

Type I IFNs (IFN-α and IFN-β) exert immunomodulatory effects and antagonize the replication of SARSCoV-1 and MERS-CoV [2, 54]. The synergistic effect of IFN-β with ribavirin suppresses the early phase viral replications, therefore, reducing the risk of transmission [55]. The IFN tau supplement increases Bacteroides & decreases Firmicutes, expressing IL-17 to protect mice [6, 56]. Similar results were obtained in multiple sclerosis patients receiving IFNβ-1b, would warrant more developmental studies for further justifications [7]. However, IFNβ-1a has given the potential safety effects to treat COVID-19 patients (NCT04343768) [57]. IFN-γ administration induces signal transducer and activation of transcription 1/&3 (STAT1/& STAT 3) to upregulate Reg3 and α-defensin to maintain homeostasis against alcohol induced intestinal disruption and elevated endotoxin level and hepatic inflammation (mice model) [58].

Corticosteroids

The corticosteroids influence NF-kB and activator protein (AP-1) to modulate their effects to activate the transcription of anti-inflammatory factors and reduce the proinflammatory cytokines production, therefore, offset the ‘cytokine storm’ formation [59]. Corticosteroids based therapies were used in SARS outbreak in 2003, and are being used in COVID-19 patients too. A synthetic glucocorticoid methylprednisolone administration in ARDS patients could decrease the risk of death by 62%, but not in all cases [8]. In contrary, the corticosteroids also reported to increase the clinical symptoms, inflammation and computed tomography (CT) abnormalities, could remain non-effective during prolonged ventilation and prompt the secondary infections [60]. Dexamethasone (DEX), 9-fluoro-glucocorticoid, acquires anti-inflammatory and immunosuppressive attributes found to reduce death rates 30% in patients on ventilation and is being widely used to treat asthma, allergies and autoimmune disorders (Table 2) [61]. Glucocorticoids influence the gut physiological functions and help retain the growth of Bifidobacterium and Lactobacillus bacteria in mice [62]. But higher dose level of corticosterone upregulates the GC receptor expression in peripheral tissues may cause physiological alterations and circadian rhythm disorder [63]. The effectiveness of corticosteroids on COVID-19 patients remains conclusive. A meta-analysis of large multinational recovery trials recruiting 20,197 patients (44 studies) using corticosteroids, have shown 28% reduction in mortality rates. However, in another trial with 4451 patients revealed the increasing mortality risks by twofolds [9].Table 3 The interventional studies are being carried out using probiotics in COVID-19 individuals with expected outcome (ClinicalTrials.gov—U.S. National Library of Medicine)

Clinical trial (randomized &controlled studies)	Title of the study	Intervention (dietary supplements)	Expected outcome	
NCT04390477	The intestinal Microbiota as a therapeutic target in hospitalized patients with COVID-19 infection	1 × 109 CFU probiotic with maltodextrin/one capsule for 30 days	Positive effects led to produce less severe clinical evolution of the disease with -ve PCR and antigen test	
NCT04458519	Efficacy of intranasal Probiotic Treatment to reduce severity of symptoms in COVID-19 infection	Nasal irrigation with Probiorinse-2.4 billion CFU of Lactobacillus lactis W-136 (NPN 80085895) twice daily for 14 days	Change in the severity of COVID-19 infection ≥ 35 on visual analogue scale (VAS)	
NCT04366180	Evaluation of probiotic Lactobacillus coryniformis K8 on COVID-19 prevention on healthcare workers	Lactobacillus K8(3 × 109 CFU) a capsule per day during 2 months	COVID-19 preventive study on healthcare workers, including fatigue status and gastrointestinal symptoms	
NCT04517422	Efficacy of Lactobacillus plantarum and Pediococcus acidilactici in adults with SARSCoV-2 & COVID-19	Probiotics L. plantarum (CECT 7481), L. plantarum (CECT 7484), L. plantarum (CECT 7485) and Pediococcus acidilactici (CECT 7483) with maltodextrin (E 1400 qs) formulated in vegetable hydroxymethylpropyl cellulose capsule	Severity progression, stay at ICU for 30 days and mortality ratio, change in viral load, IgM, IgG, fecal microbiome and serum biomakers	
NCT04399252	A randomized trial of the effect of Lactobacillus on microbiome of household contacts exposed to COVID-19	Lactobacillus rhamnosus GG, 2 capsule/day for 28 days	Incidences of one or more symptoms of COVID-19 during study period, change in microbiome shannon diversity ( fecal and nasal)	
NCT04420676	Synbiotic therapy of gastrointestinal symptoms during COVID-19 infection: A randomized double-blind placebo-controlled Telemedicine study (Syn CoV Study)	Omnibiotic (Probiotic mixture) AAD twice a day: Bifidobacterium bifidum W23, B. lactis W51, Enterococcus faecium W54, Lactobacillus acidophilus W37, Lactobacillus acidophilus W55, L. paracasei W20, L. plantarum W1, L. plantarum W62, L. rhamnosus W71, and L. salivarius W24; are mixed with maize starch, inulin, potassium chloride, hydrolysed rice protein, magnesium sulphate, fructooligosaccharide (FOS), enzymes (amylases), vanilla flavour and manganese suphate	Stool Calprotectin level measurement, duration and severity of COVID-19, stool zonulin for IBD, microbiome composition	
NCT04507867	Effects of Nutritional support system to reduce complications in patients with COVID-19 and co-morbidities in stage III	Combination of Vit B1, B6 and B12, 10 mg sol./24 h for 5 days

Probiotic Saccharomyces boulardii CNCM I-745 “Floratil” (250 mg capsule) twice a day for 6 days

Nutritional support system NSS-1 in water 400 ml

	Overall survival after 40 days completion, progression to mechanical ventilation, post COVID syndrome PHQ-9 test for mental disorders, organ failure assessment, cellular and biochemical tests in deceased patients	
NCT04581018	An evaluation of a symbiotic formula for symptoms improvement in hospitalized patients with COVID-19 infection	Health supplements (Synbiotics daily) plus standard care for 28 days	Combined symptom score and clinical improvement, SARSCoV-2 Abs development, hospital stay, life quality, time to -ve PCR, microbiome change, mortality rate	
NCT04621071	Evaluation of the efficacy of probiotics to reduce the duration and symptoms of COVID-19 (PROVID-19) study	Probiotics 2 strains (10 × 109 CFU)-2 capsules (one to swallow and 2nd one mixed with maple syrup)/day for 10 days and only one closed capsule from day 11–25	Duration of symptoms to disappear and severity of COVID-19, evolution of oral fecal microbiota	
NCT04666116	Change in viral load of patients with COVID-19 disease after dietary supplementation with probiotics	Probiotics	Viral load assessment during the period of admission, IL-6 analysis, mobility, microbiome analysis,  for 1 year time frame	
NCT04730284	Evaluation of symbiotic formula in patients with COVID-19	Health supplements tailor made synbiotics—4 g/day for 28 days	Changes in gut microbiomeβ, fecal bacteria metabolites, cytokines IL-6, IL-1β, TNF-α, CXCL-10 and trends in symptoms score	
NCT04734886	Exploratory study on the effects of probiotic supplementation on SARSCoV-2 Ab response in healthy adults	Lactobacillus reuteri DSM 17938, 1 × 108 CFU + Vit D 10 ug-2 capsule per day for 6 months	Change in SARSCoV-2 specific antibodies, IgA level, activation of innate immune molecules and adaptive immune cells.	
NCT04756466	Multicentre, randomized, double blinded parallel group pilot study to evaluate the effect of consumption of Lactobacillus strains on the incidence of COVID-19 in elderlies	Lactobacillus probiotic 3 × 109 CFU per day during 3 months	Incidence of SARSCoV-2 infection confirmed by PCR, IgA, IgG, fatigue status, gastrointestinal symptoms and pharmacological treatment	
NCT04793997	Covid-19 Primary Care Support with Microbiome Therapy	Throat spray with 3 Lactobacilli strains daily for 2 weeks	Changes in severity symptoms of COVID-19 patients in 3 weeks, Ab level and change in pathogens after spray	
NCT04798677	Multicomponent intervention (clinical and nutritional) resulting from the administration of influenza or COVID-19 vaccine and supplementation with ABBC-1	ABBC1 immunoessential: Yeast β glucan complex with consortium of Saccharomyces cerevisiae + Selenium and Zn	Alteration in acute immune response after influenza & COVID-19 vaccine ( B&T cells status) in 35 days	
NCT04813718	Post COVID-19 syndrome, A-pilot study to explore the gut -lung axis	Pre and probiotic, omni-biotic pro Vi5	Microbiome composition along with other biomarkers -T & B cells, neutrophils and monocytes function test, ILs and TNF-α measurement	
NCT05080244	Evaluation of efficacy of probiotics taken during the acute phase of COVID-19 to reduce the occurrence of long COVID	Probiotics: 2 strains 10 × 109 CFU/capsule ( 2 capsules /day 1 closed and 1 with maple syrup for 10 days, and 1 capsule for the following 15 days)	Patients with long COVID symptoms after 90 days of COVID-19 diagnosis (COVID-19 symptoms, anxiety, functioning difficulties etc.)	
NCT05043376	Study to investigate the treatment effects of Probiotic Streptococcus salivarius K12 in hospitalized patients (Non -ICU) with COVID-19	BLIS K12—2 tablets/day up to 14 days	Clinical improvement including inflammatory markers-recovery with live discharge	
NCT04950803	A randomized-controlled Trial of an Oral Microbiome Immunity Formula in Reducing Development of Long-term Co-morbidities in Recovered COVID-19 patients	3 Bifidobacteria 10 billion CFU/Sachet (1 Sachet for 6 months)	A composite outcome of any comorbidity + manifestation of Long COVID, fecal microbial metabolites and inflammatory cytokines profile	
NCT04941703	Investigation of choice alteration of Gut metagenome on COVID-19 severity	Magnesium citrate fluid 296 ml + probiotics 2 capsules twice daily for 6 days	Change in COVID-19 status on the ordinal outcome scale after 7 days	
NCT04937556	Randomized, double-blind, Placebo-controlled study to evaluate the effect of Lactobacillus probiotic strain in the immune response in participants positive for SARS-CoV-2 infection	Probiotic Lactobacillus salivarius 1 × 109 CFU + Vit D and + Zn—one capsule daily for 28 days	IgM and IgG anti-SARS CoV-2 antibodies + pro & anti inflammatory biomarker's measurement in 1 month	
NCT04922918	Administration of Ligilactobacillus salivarius MP101 in an elderly nursing home during the COVID pandemic	Administration of Ligilactobacillus salivarius MP101 > 9 log 10 CFU daily for 4 months in fermented milk	Daily activities status and fecal and nasal immune profile 37 plex	
NCT04907877	Role of nutritional support with Probiotics in Adults Outpatients with Symptomatic COVID-19: A randomized dietary study	NordBiotic ImmunoVir mixture: Bifido and Lactobacteria administered (5 billion) once a day for 28 days	Clinical symptom score of disease from healthy to worst outcome, hospitalization rate, time of recovery in 28 days' time frame, IgG response upto 6 months	
NCT04884776	Modulation of Gut Microbiota to enhance Health and Immunity of vulnerable individuals during COVID-19 Pandemic	Probiotics-3 Bifidobacteria (10 billion CFU per sachet)-2 sachets/day for 12 weeks	IgG and IgM profile, change in gut microbiota level, inflammatory and glycaemic profile  in 1, 6 and 12 months	
NCT04877704	The effects of symprove, a multi-strain Probiotic, as an Adjuvant in the Management of COVID-19 in Hospitalized Patients	Symprove probiotics	Length of Hospital Stay, intestinal inflammation, symptoms recovery in 3 months	
NCT04854941	Efficacy of probiotics (Lactobacillus rhamnosus, Bifidobacterium bifidum, Bifidobacterium longum subsp. Infantis and Bifidobacterium longum) in the treatment of hospitalized patients with Novel coronavirus infection	Probiotics with standard patient care & medication

Lactobacillus rhamnosus PDV1705, Bifidobacterium bifidum PDV 0903, Bifidobacterium longum subsp. infantis PDV 1911 and Bifidobacterium longum PDV 2301 (109 CFU each strain)-three times per day for 2 weeks

	Disease prognosis, change in blood cells count, serum albumin, serum creatinine, CRP level, bilirubin, aminotransferase level and mortality during hospitalization	
NCT04847349	Live Microbials to boost anti-SARSCoV-2 immunity clinical trial (Live basic trial)	Probiotic consortium-a capsule once a day for 21 days	Change in serum IgG, IgA and cytokine level in 21-42 days, reinfection upto 6 weeks	

Effects of antibiotics

All antibiotics including broad spectrum antibiotics like neomycin, vancomycin and metronidazole disrupt the microbiome function, thereby, activate the inflammasomes with signature of AP-1/nuclear receptor subfamily 4-group A (NR4A) to disrupt IgG 1 production (post influenza vaccine) and cause lung inflammation via M2 macrophages. The increased activation of Th1 cells and causing tissue pathology through chemokine receptor 1+ (CX3CR1+) in mononuclear phagocytosis (MNP)-dependent manner, which also alters the metabolome profile reducing the vaccine response [64]. The empirical antibiotics' treatments could lead to the loss of synbiotic bacteria in COVID-19 patients, supporting the fact of avoidance of unnecessary antibiotics use in the treatment of viral pneumonitis. Therefore, GM plays a significant role in antibiotics-host metabolism (xenobiotic) and disposition, which activates the prodrugs e.g., azo drugs to release sulfonamides [65].

The enzymes secreted by gut microbiota help metabolize the antibiotics to facilitate some important reactions e.g., acetylation, deacetylation, decarboxylation, dihydroxylation and demethylation to control the toxicity [65]. Given that the new dietary strategies could provide a clue to maintain homeostasis during COVID-19, to optimize the molecular mechanisms linked to health prospects.

Vaccines

Vaccines induce variable response depending upon the population with different ages, nutritional status, immunological response and genetic disorders. Vaccines, nevertheless, regulate the GM to attenuate and strengthen the immune response fighting against various infections. The adjuvant properties of microbiota also increase the vaccine potency and vice-versa (Table 2). Microbiota on different vaccine administration sites may also play a significant role e.g., nucleotide binding oligomerization domain-containing protein 2 (NOD2) sensing is associated with intranasal route and IgA induction is mostly associated with attenuated influenza vaccine. The skin microflora influences the vaccines response given by intradermal route [10].

The live attenuated Bacillus Calmette Guerin (BCG) vaccine provides special protection against Mycobacterium spp. and is being used for many years reducing the infant mortality. The heterologous immune response exerted by this vaccine also protects against other respiratory infections [66]. This sort of protection develops in built memory through innate immune cells and reprogram the specific genes in monocytes through regulatory elements associated with histones directly linked to modulate the metabolic and epigenetic disorders, denoted as ‘trained immunity’. The monocyte cells (ex-vivo) were found to reprogram the promoter region of genes to produce anti-inflammatory cytokines to regulate the response through GM. Vaccine response may influence the adjuvant properties of GM that activate the innate and adaptive immune response [67]. The oral presence of E. coli in antibiotic treated GF mice had helped restoring the antibody response against influenza vaccine. The antibiotics driven dysbiosis may lead to dysregulate the immune response to vaccines, including BCG. In all cases, restoration of commensal microbiota reverted the impaired antibodies response [68].

BCG could be used to treat other ailments viz., bladder cancer, warts, leishmaniasis, candidiasis and asthma [66].

The serum treated GF mice have revealed that TLR5 were sourced from commensals microflora, responsible to enhance the immune response against influenza vaccine. Similar results obtained using polio and cholera vaccines, have shown a correlation between GM composition and development of  systemic and oral immunogenic response against vaccines in infants. The overall adjuvanting traits of commensals, nonetheless, are influenced by various factors such as, vaccine formulation, routes of immunization, to establish the immune regulation and GM stability [69]. Besides, the flagellin & peptidoglycan-muramyl dipeptide (MDP) acts agonist of NOD2 sensors to enhance its adjuvant properties against cholera toxin in mice. Similarly, the use of monophosphoryl lipid-A (MPL-A) of LPS to be recognized by TLR 4 could enhance the adaptive response during vaccination [69].

Lower abundance of Bifidobacterium adolescentis could reduce the NAb response using BNT162b2 vaccine. Bifidobacteria regulate the glycolysis pathways to produce lactate, acetate/or propionate being utilized by other commensals effectively, thus, maintain the gut balance to provide the high titre of NAbs against CoronaVac. Body mass index and body weight are responsible for reducing neutralization titre even with Bifidobacterium adolescentis,  Butyricimonas virosa, Adlercreutzia equolifaciens and Asaccharobacter celatus in CoronaVac vaccine [70]. Ruminococcus torques, Eubacterium ventriosum and Streptococcus salivarius are the high responders to vaccines. Prevotella copri and Megamonas spp. are associated with less adverse events. A higher prevalence of Prevotella copri was linked with farnesoid X receptor signaling via modulating bile acid metabolism [71]. Megamonas funiformis could ferment glucose into acetate and propionate to maintain homeostasis and Megamonas hypermegale could regulate the T17 helper cells [72]. L. plantarum is reported to increase the influenza specific IgA & IgG. The long-term implications of using these commensals to enhance vaccine efficacy and potency are yet to be revealed.

Immunological dynamics

The discussion section is mainly based upon the immunological dynamics involving the immune cells and innate immune entities to modulate the response utilizing nutraceuticals and pharmacological agents through GM (Tables 1, 2 & 3, Figs. 1 & 2).

Nutraceutical—immunity dynamics

The prospects of utilizing the probiotics as complementary therapeutics are being increased due to their adjuvant properties on dendritic cells DCs & NK-cells, and induce mucosal Abs secretion, regulate IFNs, produce SCFAs and MAMPs to engage the microbial sensors e.g., PPRs/TLRs regulating the CD4+ T-cells. Probiotics help improve intestinal metabolic and GM integrity and reduce the mitochondrial stress. Hence, mitigating the risks associated with respiratory infections with influenza, rhinovirus and respiratory syncytial virus [2, 27, 37]. Probiotic therapy has not yet been fully investigated and standardised in terms of safety and efficacy against COVID-19 and other infectious diseases.

The G-proteins coupled receptors (GPRs) react with SCFAs to activate the anti-inflammatory cascade, which inhibits IL-2 & upregulate IL-10 production in monocytes. It also controls the pro-inflammatory molecules like TNF-α, IL-1, but regulate NF-kB [28–30, 36].

There is an inverse correlation between high fibre diets and inflammatory markers of serum CRP, IL-6, IL-18, and TNF-α, thus attenuating the inflammasome complexes [31]. The SCFAs secreted through pre and probiotic treatments enter the immune cells and expressed in adipose tissues through GPRs-GPR 41 &43. The receptors GPR 41 and GPR 109 lead SCFAs to metabolize into acetyl CoA to regulate TCA cycle for cell function (Fig. 1) [32, 73–75]. SCFAs also inhibit the activity of histone deacetylase (HDAC) (Fig. 1) to control the process of deacetylation and histone crontonylation leading to acetylation involved in the post-translational modification, hence, regulating NF-kB [21, 28, 33, 36]. HDAC enzymes remove the acetyl groups from lysin residues in the NH2 terminal tails of core histones form more closed chromatin structure to repress the gene expression. Hence, SCFAs naturally help through nucleus to control HDACs facilitating the gene changes to regulate the chromatin architecture critical for epigenetic modification during cell cycle and differentiation. In this way, the immune cells keep themselves in active state during the antigen processing [32, 73, 74].

Treg cell differentiation also induced via SCFAs, as it plays a role as HADC-inhibitor to intensify the histone acetylation in Foxp3 and Il10 gene loci. It also impedes the stress of inflammatory macrophages and neutrophils being produced during infection. The aryl hydrocarbon receptors/ligands (AHR) were reported to develop innate lymphoid cells (ILC), especially, IL-22 and 3 ILC 3s [32]. The indole and IPA also modulate the cells to produce antibodies (Figs. 1 & 2).

Vitamin D via VDR receptors, induces the antimicrobial cathelicidin in macrophages and synthesize α-defensin to control viral replication by synthesizing antimicrobial peptides (AMPs) that damage the envelop structure of influenza A and respiratory syncytial viruses. It reduces the conc. of proinflammatory cytokines, but increase anti-inflammatory cytokines, therefore, increase apoptosis and autophagy through cellular and viral factors controlling the lymphocytopenia [38]. It maintains the intestinal integrity and eubiosis [38, 40, 42, 76]. Vitamin A, retinoic acid, also plays an important role in regulating the differentiation, maturation, and function of innate immune response.

The ω-3 PUFAs can be metabolized into a range of lipid mediators collectively called as ‘Specialized Pro-resolving mediators’ such as, prostaglandins, leukotrienes, thromboxanes, maresins, protectins and resolvins are utilized by the immune regulatory system [77]. The macrophage cells’ activities are influenced through ω-3 PUFAs, which add phospholipids in neutrophils. Dietary ω-3 PUFAs downregulate the IL-2 driven CD4+ and CD8+ T-cell activation and upregulate the Th2 CD4+ T-cells. Hence, the direct suppression of IL-2 induced Th1 cells, indirectly enhance the cross-regulatory function of Th2 cells exert anti-inflammatory effects (Fig. 1) [16].

Flavonoids could be useful during infection, as they increase Treg and T17 cell activity. They also suppress the TLR4, reduce the 1kB phosphorylation to reduce the activity of NF-kB [28, 36]. Flavonoids hinders the growth of pathogens-Clostridium spp., Helicobacter pylori, Escherichia coli, and Salmonella typhimurium [17].

Pharmacological—immunity dynamics

The defeated IFN activities indicate the susceptibility to contract mycobacterial diseases. The interferon α-2 protein receptors i.e., IFNA2 and IFNA6 were reported to be upregulated in hospitalized patients. The IFNA2 is linked with IFN transcription in immune cells to produce cytokines and chemokines. Furthermore, IFNA2 activity decreases with seroconversion, but IFNA6 don’t (Fig. 1) [78]. SARSCoV-2 virus replication is also inhibited using IFNs in vitro (Vero and Calu3 cells), which induce the STAT1 phosphorylation in late infection [79].

Dexamethasone subsides the inflammatory cells and activates specific neutrophils against the virus, thereby, conforming the synergistic & potent therapeutic effects. Seropositive patients are not supposed to treat straightaway with antibody cocktail. Hence, the supplementation with dexamethasone was initiated in patients even who needed the oxygen support. Moreover, the anti-IL-6 (tocilizumab and sarilumab) is advised in patients who require oxygen having CRP level < 50 [80].

The antibiotics driven dysbiosis could alter the functions of many immune cells increasing the hyperactivity of intestinal macrophages and activation of pro-inflammatory helper T cells (Th) with depleted microflora, therefore, highly impeded SCFAs level increase the opportunity to contract more resistant infections [80]. The activation of M2 macrophages in lungs promote the allergic airway inflammation. The increased activation of Th1 cells causing tissue pathology through chemokine receptor 1 (CX3CR1+) & mononuclear phagocytosis (MNP)-dependent manner tend to alter the metabolome profile could diminish the vaccine response [64, 82]. GM metabolite IPA displays antibiotic properties against MDR Mycobacterium spp. and non-Mycobacterial spp., which is a deamination analogue of tryptophan and acts as an allosteric inhibitor to the tryptophan secreted by Mycobacterium and blocks the synthesis of latter amino acids in vitro & in vivo [83].

The trained immunity produced by BCG could confer the protection against SARSCoV-2, including elderlies. It can also improve the protection against the HPV warts, increase the Ab production against influenza A (H1N1) and encephalomyocarditis, reduce the clinical symptoms with HSV virus to provide protection in experimental animals against HSV1&2 etc. [84]. The earlier studies have shown that BCG activates DCs & myeloid cells to increase I-III IFN and IL-28/29 production, and reduce the IFN-α and IFN-β production giving a strategy for establishing immunity against SARSCoV-2 [85]. The coronavirus associated gastroenteritis is controlled by Enterococcus faecium in piglets. The increased production of nitric oxide in the cells treated with E. faecium expressed IL-6 and IL-8 results in stimulating the cellular immunity to fight against TGEV infection [25].

TLRs/or PRRs and NOD-like receptors on DCs provide active protection via. adjuvanted GM. TLR-5 mediated signals yield effective Abs response against influenza vaccine [10]. Trimix, with CD70 and CD40 ligands and activated TLR4 (immune activator proteins) are recognized as effective adjuvant for mRNA to be encoded with similar sequences. The SCFAs induce higher Ab response via. effective stimulation of B-cells. Therefore, Bifidobacterium adolescentis was linked with higher NAbs titre in subjects who received CoronaVac to overcome the waning immunity of inactivated vaccines.

Conclusion

It has been revealed that L. rhamnosus GG can prevent viral associated pneumonia (VAP) in high-risk ICU population [23]. More peer reviewed information is required to validate the efficacy of L. rhamnosus GG. Some studies, nonetheless, also suggest using probiotics could restrain other coronavirus associated gastroenteritis. The restoration of commensals may also revert the impaired antibodies response. The earlier studies have shown that BCG activates DCs & myeloid cells to increase IFN I-III and IL-28/29 production, and reduce the excessiveness of IFN-α and IFN-β giving a strategy for establishing immunity against SARSCoV-2 [85]. IFNs induce the STAT and JAK pathway to control viral infection in vitro. The open reading frames, ORF3b &ORF6, are antagonists to IFNs harbouring the diagnostic significance to inform disease prognosis, treatment options and animal model developments [79].

Megamonas funiformis and Megamonas hypermegale have been explored to sustain metabolic and T17 helper cells’ regulation [72]. Similarly, L. plantarum was reported to enhance influenza IgA and IgG.

The combinational therapy with pre and probiotics followed by vaccinations could have adjuvant effects in controlling the waning NAb titres. It is hypothesized that the future microbiota interventions may significantly improve the response to vaccines. Bifidobacterium adolescentis was linked with higher NAbs titre in subjects received CoronaVac to overcome the waning immunity of inactivated vaccines.

BNT162b2 vaccine elicited improved NAb response correlated to microbiota abundance with Bifidobacterium and Roseburia spp. [70]. Therefore, it is imperative the optimize involved therapies, while detecting microbial abundance. Probiotics and prebiotics supplements restore the diversity of gut microbiota, to regulate TLRs balancing the induction of pro-inflammatory and immune-regulatory cytokines conferring the viral clearance from lungs and gut to reduce the local and systemic pathogenicity. Hence, protect the body organs from permanent damage (Fig. 2) [20].

European food safety authority has already developed guidance in 2012 for safer use of E. faecium and implemented the viability assays revealing the complete protection against enteropathogenic coronavirus transmissible gastroenteritis virus (TGEV), in a dose-dependent rescue process [25]. Therefore, exploitation of these microbes offers the strategies to combat the viral gastroenteritis or IBD in humans.

Corticosteroids, vaccines, anti-sera, interferon therapies along with necessary nutraceutical supplements can enhance the protective immune response. Probiotic interventions at optimal dose level could minimize the debilitated effects in patients with improved symptomatic outcomes, therefore, shorten the stay in hospitals.

Some challenges are yet to be resolved e.g., over dose of probiotics can cause nausea and bloating. The comorbid status of patients should also be taken under consideration while using probiotics. The cohort study models should be designed to assess the errored immune signals, especially with people from underlying/comorbid conditions. Using risk free nutraceuticals trials irrespective of other medications’ regimens would certainly deliver various clues for personalized treatments to restore and sustain health. On the other hand, probiotics can also contribute to the antibiotic resistant genes, which may exchange thoroughly among commensals. This also provides clues to establishing strategies as how the health is impacted in clinic/hospital environment than at home. More research could be executed to study the impact of active foods on antibiotic susceptibility. A synergistic relationship among bacteriophages, essential probiotics, other commensals and how these implicate the immune cells modulation, including the environments contributing to the antibiotic resistance. Efficacies of ω-PUFA, other vitamins and dietary fibres along with probiotics is yet to be determined among different group of patients at different severity levels from asymptomatic to symptomatic. Last but not least, would probiotics really improve the potency of molecular vaccines to combat the problems of waning immunity, is yet to be revealed?

Abbreviations

ARDS Acute respiratory distress syndrome

AP1 Activator protein

AMP Antimicrobial peptides

CCL3 Chemokine C–C motif ligand 3

CRP or hsCRP C-reactive protein

Calu32B4 cells Cellosaurus cell line

BCG Bacillus Calmette Guerin

CCl2 Chemokine

CD40 Cluster of differentiation-40

DCs Dendritic cells

DAT Desaminotyrosine

DEX Dexamethasone

DEFA5 Defensin α 5

FMF Familial Mediterranean fever

GPXs Glutathione peroxidases

GPR G-protein coupled receptor

HDAC Histone deacetylases

HSV Herpes simplex virus

IL Interleukin

IFNA Interferon alpha protein

IFN Interferon

LCHV Bacteriocin acidocin

MAMPs Microbe Associated Molecular Patterns

MCP-1 Monocyte chemoattractant protein-1

MIP-1α Macrophage inflammatory protein-1α

MNP Mononuclear phagocytosis

MMP7 Matrix Metalloproteinase 7

NK cells Natural Killer cells

NF–kB Nuclear factor kappa-light-chain-enhancer of activated B cells

NOD2 Nucleotide binding oligomerization domain-containing protein-1

NAb Neutralizing antibodies

NR4A Nuclear receptor subfamily 4, NOR1  group A related to neuron derived orphan receptor 1

ORF Open reading frame

PRXs Peroxiredoxins

PRR Pattern Recognition Receptors

ROS Reactive Oxygen Species activation

RdRp RNA dependent RNA polymerase

SCFAs Short chain fatty acids

SOD Superoxide dismutase

STAT 1 Signal Transducer and Activation of Transcription

TNF-α Tumour necrosis factor–α

Th cells T helper cells

TGEV Enteropathogenic coronavirus transmissible gastroenteritis virus

TjP Tight junction protein

TCA Tricarboxylic acid cycle

VAP Viral associated pneumonia

VDR Vit D receptors

ω-3 PUFAs Omega-3-polyunsaturated fatty acids

Acknowledgements

Author is thankful to all the scientists have contributed their remarkable work in the field. All the research literature is sourced from an open Google-Pub Med platform. Without expert reviewers’ assistance, this work would have been remained impossible. Their vital insights have re-shaped this manuscript systematically.

Author contributions

Author has read and approved the final manuscript.

Funding

No fund/grant has been received for the preparation of this manuscript.

Availability of data and materials

Not applicable.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Author has read and approved the final manuscript for publication.

Competing interests

Author has declared no conflict of interest.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Sarkar A Harty S Moeller AH Klein SL Erdman SE Friston KJ Carmody RN The gut microbiome as a biomarker of differential susceptibility to SARS-CoV-2 Trends Mol Med 2021 27 12 1115 1134 10.1016/j.molmed.2021.09.009 34756546
Sarkar A, Harty S, Moeller AH, Klein SL, Erdman SE, Friston KJ, Carmody RN. The gut microbiome as a biomarker of differential susceptibility to SARS-CoV-2. Trends Mol Med. 2021;27(12):1115-34.34756546
2. Kaushal A Noor R Association of gut microbiota with inflammatory bowel disease and COVID-19 severity: a possible outcome of the altered immune response Curr Microbiol 2022 79 184 10.1007/s00284-022-02877-7 35508737
Kaushal A, Noor R. Association of gut microbiota with inflammatory bowel disease and COVID-19 severity: a possible outcome of the altered immune response. Curr Microbiol. 2022;79:184. 10.1007/s00284-022-02877-7.35508737
3. Lordan R, Rando HM. COVID-19 Review Consortium, Greene CS. Dietary Supplements and nutraceuticals under investigation for COVID-19 prevention and treatment. ArXiv. arXiv:2102.02250v1. Msystems. 2021;6(3).
4. Kaushal A Immune response and pathogenesis of COVID-19 and strategies for developing the target drugs Acta Sci Microbiol 2020 3 92 102 10.31080/ASMI.2020.03.0682
Kaushal A. Immune response and pathogenesis of COVID-19 and strategies for developing the target drugs. Acta Sci Microbiol. 2020;3(9):92-102.
5. Barrea L Grant WB Frias-Tora E Vetrani C Verde L de Alteriis G Docimo A Savastano S Calao A Muscogiuri G Dietary recommendations for post-COVID-19 syndrome Nutrients 2022 14 6 1305 10.3390/nu14061305 35334962
Barrea L, Grant WB, Frias-Toral E, Vetrani C, Verde L, de Alteriis G, Docimo A, Savastano S, Calao A, Muscogiuri G. Dietary recommendations for post-COVID-19 syndrome. Nutrients. 2022;14(6):1305. 10.3390/nu14061305.35334962
6. Ren W Chen S Zhang L Liu G Hussain T Hao X Interferon tau affects mouse intestinal microbiota and expression of IL-17 Mediators Inflamm 2016 2016 2839232 10.1155/2016/2839232 27610003
Ren W, Chen S, Zhang L, Liu G, Hussain T, Hao X, Yin J, Duan J, Tan B, Wu G, Bazar FW, Yin Y. Interferon tau affects mouse intestinal microbiota and expression of IL-17. Mediators Inflamm. 2016;2016:2839232.27610003
7. Castillo-Alvarez F Perez-Matute P Oteo JA Marzo-Sola ME The influence of interferon beta-1b on gut microbiota composition in patients with multiple sclerosis Neurologia 2016 36 7 495 503
Castillo-Alvarez F, Perez-Matute P, Oteo JA, Marzo-Sola ME. The influence of interferon β-1b on gut microbiota composition in patients with multiple sclerosis. Neurologia (Engl ED). 2021;36(7):495–503.
8. Ling Y Xu SB Lin YX Tian D Zhu ZQ Dai FH Wu F Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients Chin Med J (Engl) 2020 133 9 1039 1043 10.1097/CM9.0000000000000774 32118639
Ling Y, Xu SB, Lin YX, Tian D, Zhu ZQ, Dai FH, Wu F, Song ZG, Huang W, Chen J, Hu BJ, Wang S, Mao EQ, Zhu L, Zhang WH, Lu HZ. Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients. Chin Med J (Engl). 2020; 133(9):1039–1043.32118639
9. Chaharom FE Pourafkari L Chaharom EAA Nadera ND Effects of corticosteroids on COVID-19 patients: a systematic review and meta -analysis on clinical outcomes Pulm Pharmacol Ther 2022 72 102107 10.1016/j.pupt.2021.102107 34933068
Chaharom FE, Pourafkari L, Chaharom AAE, Nader ND. Effects of corticosteroids on COVID-19 patients: a systematic review and meta -analysis on clinical outcomes. Pulm Pharmacol Ther. 2022;72:102107. 10.1016/j.pupt.2021.102107.34933068
10. Lynn DJ Benson SC Lynn MA Pulendran B Modulation of immune responses to vaccination by the microbiota: implications and potential mechanisms Nat Rev Immunol 2022 22 1 33 46 10.1038/s41577-021-00554-7 34002068
Lynn DJ, Benson SC, Lynn MA, Pulendran B. Modulation of immune responses to vaccination by the microbiota: implications and potential mechanisms. Nat Rev Immunol. 2022;22(1):33–46.34002068
11. May C-A Scholkmann F COVID-19, post-acute COVID-19 syndrome (PACS, “long COVID”) and post-COVID-19 vaccination syndrome (PCVS, “post-COVIDvac-syndrome”): similarities and differences Pathology Res Pract 2023 246 154497 10.1016/j.prp.2023.154497
Scholkmann F, and May CA. COVID-19, post-acute COVID-19 syndrome (PACS, “long COVID”) and post-COVID-19 vaccination syndrome (PCVS, “post-COVID vac-syndrome”): similarities and differences. Pathology Res Pract. 2023;246:154497.
12. Gezginç Y Karabekmez-Erdem T Tatar HD Ayman S Ganiyusufoglu E Dayisoylu KS Health promoting benefits of postbiotics produced by lactic acid bacteria: exopolysaccharide Biotech Stud 2022 31 61 70 10.38042/biotechstudies.1159166
Gezginç Y, Karabekmez-Erdem T, Tatar HD, Ayman S, Ganiyusufoglu E, Dayisoylu KS. Health promoting benefits of postbiotics produced by lactic acid bacteria: exopolysaccharide. Biotech Stud. 2022;31:61–70. 10.38042/biotechstudies.1159166.
13. Thorakkattu P Khanashyam AC Shah K Babu KS Mundanat AS Deliephan A Deokar GS Santivarangkna C Nirmal NP Postbiotics: current trends in food and pharmaceutical industry Foods 2022 11 19 3094 10.3390/foods11193094 36230169
Thorakkattu P, Khanashyam AC, Shah K, Babu KS, Mundanat AS, Deliephan A, Deokar GS, , Santivarangkna C, Nirmal NP. Postbiotics: current trends in food and pharmaceutical industry. Foods. 2022;11(19):3094. 10.3390/foods11193094.36230169
14. Watson H Mitra S Croden FC Taylor M Wood HM Perry SL Spencer JA Quirke P Toogood GJ Lawton CL A randomised trial of the effect of omega-3 polyunsaturated fatty acid supplements on the human intestinal microbiota Gut 2018 67 1974 1983 10.1136/gutjnl-2017-314968 28951525
Watson H, Mitra S, Croden FC, Taylor M, Wood HM, Perry SL, Spencer JA, Quirke P, Toogood GJ, Lawton CL, Dye L, Loadman PM, Hull MA. Arandomised trial of the effect of omega-3 polyunsaturated fatty acid supplements on the human intestinal microbiota. Gut. 2018;67(11):1974–83.28951525
15. Mazidimoradi A Alemzahdeh E Alemzadeh E Salehiniya H The effect of polyunsaturated fatty acids on the severity and mortality of COVID-19 patients: a systematic review Life Sci 2022 229 120489 10.1016/j.lfs.2022.120489
Mazidimoradi A, Alemzahdeh E, Alemzadeh E, Salehiniya H. The effect of polyunsaturated fatty acids on the severity and mortality of COVID-19 patients: a systematic review. Life Sci. 2022;299:120489.
16. Arrington JL Chapkin RS Switzer KC Morris JS McMurray DN Dietary n-3 polyunsaturated fatty acids modulate purified murine T-cell subset activation Clin Exp Immunol 2001 125 3 499 507 10.1046/j.1365-2249.2001.01627.x 11531960
Arrington JL, Chapkin RS, Switzer KC, Morris JS, McMurray DN. Dietary n-3 polyunsaturated fatty acids modulate purified murine T-cell subset activation. Clin Exp Immunol. 2001;125(3):499–507. 10.1046/j.1365-2249.2001.01627.x.11531960
17. Alkhalidy H Wang Y Liu D Dietary flavonoids in the prevention of T2D: an overview Nutrients 2018 10 4 438 10.3390/nu10040438 29614722
Alkhalidy H, Wang Y, and Liu D. Dietary flavonoids in the prevention of T2D: an overview. Nutrients. 2018;10(4):438.29614722
18. Pandey KR Naik SR Vakil BV Probiotics, prebiotics and synbiotics- a review J Food Sci Technol 2015 52 12 7577 7587 10.1007/s13197-015-1921-1 26604335
Pandey KR, Naik SR, Vakil BV. Probiotics, prebiotics and synbiotics- a review. J Food Sci Technol. 2015;52(12):7577–87.26604335
19. Akour A Probiotics and COVID-19: is there any link? Lett Appl Microbiol 2020 71 3 229 234 10.1111/lam.13334 32495940
Akour A. Probiotics and COVID-19: is there any link? Lett Appl Microbiol. 2020;71(3):229–34.32495940
20. Markowiak P Slizewska K Effects of probiotics, prebiotics, and synbiotics on human health Nutrients 2017 9 9 1021 10.3390/nu9091021 28914794
Markowiak P, Slizewska K. Effects of probiotics, prebiotics, and synbiotics on human health. Nutrients. 2017;9(9):1021.28914794
21. Jabczyk M Nowak J Hudzik B Zubelewicz-Szkodzińska B Diet, probiotics and their impact on the gut microbiota during the COVID-19 pandemic Nutrients 2021 13 9 3172 10.3390/nu13093172 34579048
Jabczyk M, Nowak J, Hudzik B, Zubelewicz-Szkodzińska B. Diet, probiotics and their impact on the gut microbiota during the COVID-19 pandemic. Nutrients. 2021;13(9):3172.34579048
22. Morrow LE Kollef MH Casale TB Probiotic prophylaxis of ventilator-associated pneumonia: a blinded, randomized, controlled trial Am J Respir Crit Care Med 2010 182 8 1058 1064 10.1164/rccm.200912-1853OC 20522788
Morrow LE, Kollef MH, Casale TB. Probiotic prophylaxis of ventilator-associated pneumonia: a blinded, randomized, controlled trial. Am J Respir Crit Care Med. 2010;182(8):1058–64.20522788
23. Mahmoodpoor A Hamishehkar H Asghari R Abri R Shadvar K Sanaie S Effect of a probiotic preparation on ventilator-associated pneumonia in critically ill patients admitted to the intensive care unit: a prospective double-blind randomized controlled trial Nutr Clin Pract 2019 34 1 156 162 10.1002/ncp.10191 30088841
Mahmoodpoor A, Hamishehkar H, Asghari R, Abri R, Shadvar K, Sanaie S. Effect of a probiotic preparation on ventilator-associated pneumonia in critically ill patients admitted to the intensive care unit: a prospective double-blind randomized controlled trial. Nutr Clin Pract. 2019;34(1):156–162.30088841
24. Chan CKY Tao J Chan OS Li HB Pang H Preventing respiratory tract infections by synbiotic interventions: a systematic review and meta-analysis of randomized controlled trials Adv Nutr 2020 11 4 979 988 10.1093/advances/nmaa003 31996911
Chan CKY, Tao J, Chan OS, Li HB, Pang H. Preventing respiratory tract infections by synbiotic interventions: a systematic review and meta-analysis of randomized controlled trials. Adv Nutr. 2020;11(4):979–88.31996911
25. Chai W Burwinkel M Wang Z Palissa C Esch B Twardziok S Rieger J Wrede P Schmidt MF Antiviral effects of a probiotic Enterococcus faecium strain against transmissible gastroenteritis coronavirus Arch Virol 2013 158 4 799 807 10.1007/s00705-012-1543-0 23188495
Chai W, Burwinkel M, Wang Z, Palissa C, Esch B, Twardziok S, Rieger J, Wrede P, Schmidt MF. Antiviral effects of a probiotic Enterococcus faecium strain against transmissible gastroenteritis coronavirus. Arch Virol. 2013;158(4):799–807.23188495
26. Crouch LI, Liberato MV, Urbanowicz PA, Basle A, Lamb CA, Stewart CJ, Cooke K, Doona M, Needham S, Brady RR, Berrington JE, Madunic K,Wuhrer M, Chater P, Pearson JP, Glowacki R, Martens EC, Zhang F, Linhardt RJ, Spencer DIR, Bolam DN. Prominent members of human gut microbiota express endo -acting O-glycanases to initiate mucin breakdown. Nat Commun. Nat Commun. 2020;11(4017). 10.1038/s41467-020-17847-5.
27. Baud D Dimopoulou Agri V Gibson GR Reid G Using probiotics to flatten the curve of coronavirus disease COVID-2019 pandemic Front Public Health 2020 8 186 10.3389/fpubh.2020.00186 32574290
Baud D, Agri DV, Gibson GR, Reid G Giannoni E. Using probiotics to flatten the curve of coronavirus disease COVID-2019 pandemic. Front Public Health. 2020;8:186.32574290
28. Yang Q Liang Q Balakrishnan B Belobrajdic DP Feng QJ Zhang W Role of dietary nutrients in the modulation of gut microbiota: a narrative review Nutrients 2020 12 381 10.3390/nu12020381 32023943
Yang Q, Liang Q, Balakrishnan B,Belobrajdic DP, Feng QJ, Zhang W. Role of dietary nutrients in the modulation of gut microbiota: a narrative review. Nutrients. 2020;12(2):381.32023943
29. Ferreira C Viana SD Reis F Gut microbiota dysbiosis-immune hyperresponse-inflammation triad in coronavirus disease-2019 (COVID-19): impact of pharmacological and nutraceutical approaches Microorganisms 2020 8 10 1514 10.3390/microorganisms8101514 33019592
Ferreira C, Viana SD, Reis F. Gut microbiota dysbiosis-immune hyperresponse-inflammation triad in coronavirus disease-2019 (COVID-19): impact of pharmacological and nutraceutical approaches. Microorganisms. 2020;8(10):1514. 10.3390/microorganisms8101514.33019592
30. Idir M Strengthening the immune system and reducing inflammation and oxidative stress through diet and nutrition: considerations during the COVID-19 crisis Nutrients 2020 12 6 1562 10.3390/nu12061562 32471251
Iddir M, Brito A, Dingeo G, Campo SSFD, Samouda H, Frano MRL, Bohn T. Strengthening the immune system and reducing inflammation and oxidative stress through diet and nutrition: considerations during the COVID-19 crisis. Nutrients. 2020;12(6):1562.32471251
31. Rishi P Thakur K Vij S Rishi L Singh A Kaur IP Patel SKS Lee JK Kalia VC Diet, gut microbiota and COVID-19 Indian J Microbiol 2020 60 420 429 10.1007/s12088-020-00908-0 33012868
Rishi P, Thakur K, Vij S, Rishi L, Singh A, Kaur IP, Patel SKS, Lee JK, Kalia VC. Diet, gut microbiota and COVID-19. Indian J Microbiol. 2020;60(4):420–9.33012868
32. Corrêa Oliveira R Fachi JL Vieira A Sato FT Vinolo MAR Regulation of immune cell function by short-chain fatty acids Clin Transl Immunol 2016 5 4 e73 10.1038/cti.2016.17
Corrêa Oliveira R, Fachi JL, Vieira A, Sato FT, Vinolo MAR. Regulation of immune cell function by short-chain fatty acids. Clin Transl Immunol. 2016;5(4):e73. 10.1038/cti.2016.17.
33. Ratajczak W Rył A Mizerski A Walczakiewicz K Sipak O Laszczynska M Immunomodulatory potential of gut microbiome-derived short-chain fatty acids (SCFAs) Acta Biochim Pol 2019 66 1 1 12 30831575
Ratajczak W, Rył A, Mizerski A, Walczakiewicz K, Sipak O, Laszczynska M. Immunomodulatory potential of gut microbiome-derived short-chain fatty acids (SCFAs). Acta Biochim Pol. 2019;66(1):1–12.30831575
34. Root MM Houser SM Anderson JJB Dawson HR Healthy Eating Index 2005 and selected macronutrients are correlated with improved lung function in humans Nutr Res 2014 34 277 284 10.1016/j.nutres.2014.02.008 24774063
Root MM, Houser SM, Anderson JJB, Dawson HR. Healthy Eating Index 2005 and selected macronutrients are correlated with improved lung function in humans. Nutr Res. 2014;34(4):277–84.24774063
35. Saleri R Borghetti P Ravanetti F Cavalli V Ferrari L De Angelis E Andrani M Martelli P Effects of different short chained fatty acids (SCFA) on gene expression of proteins involved in barrier function in IPEC-J2 Porcine Health Manag 2022 8 21 10.1186/s40813-022-00264-z 35590351
Saleri R, Borghetti P, Ravanetti F, Cavalli V, Ferrari L, De Angelis E, Andrani M, Martelli P. Effects of different short chained fatty acids (SCFA) on gene expression of proteins involved in barrier function in IPEC-J2. Porcine Health Manag. 2022;8:21.35590351
36. Yang Q Tang J Xu C Zhao H Zhou Y Wang Y Histone deacetylase 4 inhibits NF-κB activation by facilitating IκBα sumoylation J Mol Cell Biol 2020 12 12 933 945 10.1093/jmcb/mjaa043 32770227
Yang Q, Tang J, Xu C, Zhao H, Zhou Y, Wang Y, Yang M, Chen X, Chen J. Histone deacetylase 4 inhibits NF-κB activation by facilitating IκBα sumoylation. J Mol Cell Biol. 2020;12(12):933–45.32770227
37. Xavier-Santos D Padilha M Fabiano GA Vinderola G Gomes Cruz A Sivieri K Costa Antunes AE Evidences and perspectives of the use of probiotics, prebiotics, synbiotics, and postbiotics as adjuvants for prevention and treatment of COVID-19: a bibliometric analysis and systematic review Trends Food Sci Technol 2022 120 174 192 10.1016/j.tifs.2021.12.033 35002079
Xavier-Santos D, Padilha M, Fabiano GA, Vinderola G, Cruz AG, Sivieri K, Antunes AEC. Evidences and perspectives of the use of probiotics, prebiotics, synbiotics, and postbiotics as adjuvants for prevention and treatment of COVID-19: a bibliometric analysis and systematic review. Trends Food Sci Technol. 2022;120:174–92.35002079
38. Martineau AR Jolliffe DA Hooper RL Greenberg L Aloia JF Bergman P Dubnov-Raz G Esposito S Ganmaa DA Ginde A Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data BMJ 2017 356 i6583 10.1136/bmj.i6583 28202713
Martineau AR, Jolliffe DA, Hooper RL, Greenberg L, Aloia JF, Bergman P, Dubnov-Raz G, Esposito S, Ganmaa D, Ginde AA, Goodall EC, Grant CC, Griffiths CJ, Janssens W, Laaksi I, Manaseki- Holland S, Mauger D, Murdoch DR, Neale R, Rees JR, Simpson Jr S, Stelmach I, Kumar GT, Urashima M, Camargo Jr CA. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. BMJ. 2017;356:i6583.28202713
39. Tangestani H Boroujeni HK Djafarian K Emamat H Shab-Bidar S Vitamin D and the gut microbiota: a narrative literature review Clin Nutr Res 2021 10 3 181 191 10.7762/cnr.2021.10.3.181 34386438
Tangestani H, Boroujeni HK, Djafarian K, Emamat H, Shab-Bidar S. Vitamin D and the gut microbiota: a narrative literature review. Clin Nutr Res. 2021;10(3):181–91.34386438
40. Entrenas Castillo M Entrenas Costa LM Vaquero Barrios JM Alcalá Díaz JF López Miranda J Bouillon R Quesada Gomez JM Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: a pilot randomized clinical study J Steroid Biochem Mol Biol 2020 203 105751 10.1016/j.jsbmb.2020.105751 32871238
Castillo ME, Costa LME, Barrios JMV, Díaz JFA, Miranda JL, Bouillon R, and Gomez JMQ. Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: a pilot randomized clinical study. J Steroid Biochem Mol Biol. 2020;203:105751.32871238
41. Baktash V Hosack T Patel N Shah S Kandiah P Van den Abbeele K Mandal AKJ Missouris CG Vitamin D status and outcomes for hospitalised older patients with COVID-19 Postgrad Med J 2021 97 1149 442 447 10.1136/postgradmedj-2020-138712 32855214
Baktash V, Hosack T, Patel N, Shah S, Kandiah P, Abbeele KV, Mandal AKJ, Missouris CG. Vitamin D status and outcomes for hospitalised older patients with COVID-19. Postgrad Med J. 2021;97(1149):442–7.32855214
42. Matin S Fauladi N The sufficient vitamin D and albumin level have a protective effect on COVID-19 infection Arch Microbiol 2021 203 5153 5162 10.1007/s00203-021-02482-5 34331101
Matin S, Fauladi N, Pahlevan Y, Asghariazar V, Molaei S, Khiavi HA, Negaresh M, Safarzadeh E. The sufficient vitamin D and albumin level have a protective effect on COVID-19 infection. Arch Microbiol. 2021 203(8):5153–62.34331101
43. Mousavi S Bereswill S Heimesaat MM Immunomodulatory and antimicrobial effect of Vitamin C Eur J Microbiol (Bp) 2019 9 3 73 79
Mousavi S, Bereswill S, Heimesaat MM. Immunomodulatory and antimicrobial effect of Vitamin C. Eur J Microbiol Immunol (Bp). 2019;9(3):73–9.
44. Pierre JF Hinterleitner R Bouziat R Hubert N Leone V Miyoshi J Jabri B Chang EB Data on changes to mucosal inflammation and the intestinal microbiota following dietary micronutrients in genetically susceptible hosts Data Brief 2018 20 387 393 10.1016/j.dib.2018.08.026 30175203
Pierre JF, Hinterleitner R, Bouziat R, Hubert N, Leone V, Miyoshi J, Jabri B, Chang EB. Data on changes to mucosal inflammation and the intestinal microbiota following dietary micronutrients in genetically susceptible hosts. Data Brief. 2018;20:387–93.30175203
45. Lee H Ko G Antiviral effect of vitamin A on norovirus infection via modulation of the gut microbiome Sci Rep 2016 6 25835 10.1038/srep25835 27180604
Lee H, Ko GP Antiviral effect of vitamin A on norovirus infection via modulation of the gut microbiome. Sci Rep. 2016;6:25835.27180604
46. Di Nicolantonio JJ Bhutani J Okeefe JH The health benefit of Vitamin K Open Heart. 2015 2 1 e000300 10.1136/openhrt-2015-000300 26468402
DiNicolantonio JJ, Bhutani J, Okeefe JH. The health benefits of Vitamin K. Open Heart. 2015;2(1):e000300. 10.1136/openhrt-2015-000300.26468402
47. Stoffaneller R Morse NL A review of dietary selenium intake and selenium status in Europe and the Middle East Nutrients 2015 7 3 1494 1537 10.3390/nu7031494 25734564
Stoffaneller R, Morse NL. A review of dietary selenium intake and selenium status in Europe and the Middle East. Nutrients. 2015;7(3):1494–537.25734564
48. Kudva AK Shay AE Prabhu KS Selenium and inflammatory bowel disease Am J Physiol Gastrointest Liver Physiol 2015 309 2 G71 G77 10.1152/ajpgi.00379.2014 26045617
Kudva AK, Shay AE, Prabhu KS. Selenium and inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol. 2015;309(2):G71–7.26045617
49. te Velthuis AJ van den Worm SH Sims AC Baric RS Snijder EJ van Hemert MJ Zn (2+) inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture PLoS Pathog 2010 6 11 e1001176 10.1371/journal.ppat.1001176 21079686
te Velthuis AJW, van den Worm SHE, Sims AC, Baric RS, Snijder EJ, van Hemert MJ. Zn2+ inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture. PLoS Pathog. 2010;6(11):e1001176.21079686
50. Zackular JP Moore JL Jordan AT Juttukonda LJ Noto MJ Nicholson MR Crews JD Semler MW Zhang Y Ware LB Washington MK Chazin WJ Caprioli RM Skaar EP Dietary zinc alters the microbiota and decreases resistance to Clostridium difficile infection Nat Med 2016 22 11 1330 1334 10.1038/nm.4174 27668938
Zackular JP, Moore JL, Jordan AT, Juttukonda LJ, Noto MJ, Nicholson MR, Crews JD, Semler MW, Zhang Y, Ware LB, Washington MK, Chazin WJ, Caprioli RM, Skaar EP. Dietary zinc alters the microbiota and decreases resistance to Clostridium difficile infection. Nat Med. 2016;22(11):1330–4.27668938
51. Patterson E O’Doherty RM Murphy EF Wall R O’Sullivan O Nilaweera K Fitzgerald GF Cotter PD Ross RP Stanton C Impact of dietary fatty acids on metabolic activity and host intestinal microbiota composition in C57BL/6J mice Br J Nutr 2014 111 1905 1917 10.1017/S0007114514000117 24555449
Patterson E,O’Doherty RM, , Murphy EF, Wall R, O’Sullivan O, Nilaweera K, Fitzgerald GF, Cotter PD, Ross RP, Stanton C. Impact of dietary fatty acids on metabolic activity and host intestinal microbiota composition in C57BL/6J mice. Br J Nutr. 2014;111(11):1905–17.24555449
52. Pérez-Cano FJ Castell M Flavonoids, inflammation and immune system Nutrients 2016 8 10 659 10.3390/nu8100659 27775647
Pérez-Cano FJ, Castell M. Flavonoids, inflammation and immune system. Nutrients. 2016;8(10):659.27775647
53. Steed AL Christophi GP Kaiko GE Sun L Goodwin VM Jain U The microbial metabolite desaminotyrosine protects from influenza through type I interferon Science 2017 357 6350 498 502 10.1126/science.aam5336 28774928
Steed AL, Christophi GP, Kaiko GE, Sun L, Goodwin VM, Jain U, Esaulova E, Artyomov MN, Morales DJ, Holtzman MJ, Boon ACM, Lenschow DJ, Stappenbeck TS. The microbial metabolite desaminotyrosine protects from influenza through type I interferon. Science. 2017;357(6350):498–502.28774928
54. Chan JF To KK Tse H Jin DY Yuen KY Interspecies transmission and emergence of novel viruses: lessons from bats and birds Trends Microbiol 2013 21 10 544 555 10.1016/j.tim.2013.05.005 23770275
Chan JFW, Wang To KK, Tse H, Jin DY, Yuen KY. Interspecies transmission and emergence of novel viruses: lessons from bats and birds. Trends Microbiol. 2013;21(10):544–55. 10.1016/j.tim.2013.05.005.23770275
55. Morgenstern B Michaelis M Baer PC Doerr HW Cinatl J Jr Ribavirin and interferon-beta synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines Biochem Biophys Res Commun 2005 326 4 905 908 10.1016/j.bbrc.2004.11.128 15607755
Morgenstern B, Michaelis M, Baer PC, Doerr HW, Cinatl J Jr. Ribavirin and interferon-beta synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines. Biochem Biophys Res Commun. 2005;326(4):905–8.15607755
56. Meng Z, Wang T, Chen L, Chen X, Li L, Qin X, Li H, Luo J. An experimental trial of recombinant human interferon alpha nasal drops to prevent COVID 2019 in medical staff in an epidemic area. Current Topics in Medicinal Chemistry. 2021;21(10):920-927. 10.2174/1568026621666210429083050.
57. Darazam IA Shokouhi S Pourhoseingholi MA Role of interferon therapy in severe COVID-19: the COVIFERON randomized controlled trial Scientific Report 2021 11 1 8059 10.1038/s41598-021-86859-y
Darazam IA, Shokouhi S, Pourhoseingholi MA, Irvani SSN, Mokhtari M, Shabani M1, Amirdosara M, Torabinavid P, Golmohammadi M, Hashemi SP, Azimi A, Maivan MHJ, Rezaei O, Zali A, Hajiesmaeili M, Dehbsneh HS , Kusha AH, Shoushtari MT, Khalili N, Soleymaninia A, Gachkar L, and Khoshkar A. Role of interferon therapy in severe COVID-19: the COVIFERON randomized controlled trial. Scientific Report. 2021;11(1):8059.
58.  Yue R, Wei X, Zhao J, Zhou Z, Zhong W. Essential role of IFN-γ in regulating Gut Antimicrobial Peptides and Microbiota to protect Against Alcohol-Induced bacterial translocation and Hepatic Inflammation in Mice. Front Physiol. 2021;11:629141. 10.3389/fphys.2020.629141
59. Barnes PJ How corticosteroids control inflammation: quintiles prize lecture Br J Pharmacol 2006 148 3 245 254 10.1038/sj.bjp.0706736 16604091
Barnes PJ. How corticosteroids control inflammation: Quintiles Prize Lecture. Br J Pharmacol. 2006;148(3):245–54.16604091
60. Zha L Li S Pan L Tefsen B Li Y French N Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19) Med J Aust 2020 212 9 416 420 10.5694/mja2.50577 32266987
Zha L, Li S, Pan L, Tefsen B, Li Y, French N, Chen L, Yang G, Villanueva EV. Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19). Med J Aust. 2020;212(9):416–420.32266987
61. Cain D Cidlowski JA Immune regulation by glucocorticoids Nat Rev Immunol 2017 17 4 233 247 10.1038/nri.2017.1 28192415
Cain DW, Cidlowski JA. Immune regulation by glucocorticoids. Nat Rev Immunol. 2017;17(4):233–247.28192415
62. Huang EY Inoue T Leone VA Dalal S Touw K Wang Y Musch MW Theriault B Higuchi K Donovan S Using corticosteroids to reshape the gut microbiome: Implications for inflammatory bowel diseases Inflamm Bowel Dis 2015 21 5 963 972 10.1097/MIB.0000000000000332 25738379
Huang EY, Inoue T, Leone VA, Dalal S, Touw K, Wang Y, Musch MW, Theriault B, Higuchi K, Donovan S, Jack Gilbert J, Chang EB. Using corticosteroids to reshape the gut microbiome: Implications for inflammatory bowel diseases. Inflamm Bowel Dis. 2015;21(5):963–972.25738379
63. Wu T Yang L Jiang J Ni Y Zhu J Zheng X Wang Q Lu X Fu Z Chronic glucocorticoid treatment induced circadian clock disorder leads to lipid metabolism and gut microbiota alterations in rats Life Sci 2018 192 173 182 10.1016/j.lfs.2017.11.049 29196049
Wu T, Yang L, Jiang J, Ni Y, Zhu J, Zheng X, Wang Q, Lu X, Fu Z. Chronic glucocorticoid treatment induced circadian clock disorder leads to lipid metabolism and gut microbiota alterations in rats. Life Sci. 2018;192:173–182.29196049
64. Hagan T Cortese M Rouphael N Boudreau C Linde C Maddur MS Antibiotics-driven gut microbiome perturbation alters immunity to vaccines in humans Cell 2019 178 6 1313 1328 10.1016/j.cell.2019.08.010 31491384
Hagan T, Cortese M, Rouphael N, Boudreau C, Linde C, Maddur MS, Das J, Wang H, Guthmiller J, Zheng NY, Huang M, Uphadhyay AA, Gardinassi L, Petitdemange C, McCullough MP, Johnson SJ, Gill K, Cervasi B, Zou J, Bretin A, Hahn M, Gewirtz AT, Bosinger SE, Wilson PC , Li S, Alter G, Khurana S, Golding H, Pulendran B. Antibiotics-Driven Gut Microbiome Perturbation Alters Immunity to Vaccines in Humans. Cell. 2019;178(6):1313–1328.31491384
65. Wilson DI Nicholson JK Gut microbiome interactions with drug metabolism, efficacy, and toxicity Transl Res 2017 2017 179 204 222 10.1016/j.trsl.2016.08.002
 Wilson ID, Nicholson JK (2017). Gut microbiome interactions with drug metabolism, efficacy, and toxicity. Transl Res. 2017;179:204–222.
66. Arts R Moorlag S Novakovic B Li Y Wang SY Oosting BCG vaccination protects against experimental viral infection in humans through the induction of cytokines associated with trained immunity Cell Host Microbe 2018 23 1 89 100.e5 10.1016/j.chom.2017.12.010 29324233
 Arts RJW, Moorlag SJCFM, Novakovic B, Li Y, Wang SY, Oosting M, Kumar V, Xavier RJ, Wijmenga C, Joosten LAB, Reusken CBEM, Benn CS, Aaby P, Koopmans MP, Stunnenberg HG, van Crevel R, Netea MG. BCG Vaccination Protects against Experimental Viral Infection in Humans through the Induction of Cytokines Associated with Trained Immunity. Cell Host Microbe. 2018;23(1):89–100.e5.29324233
67. Curtis N Sparrow A Ghebreyesus TA Netea MG Considering BCG vaccination to reduce the impact of COVID-19 Lancet 2020 395 10236 1545 1546 10.1016/S0140-6736(20)31025-4 32359402
Curtis N, Sparrow A, Ghebreyesus TA, Netea MG. Considering BCG vaccination to reduce the impact of COVID-19. Lancet. 2020;395(10236):1545–1546.32359402
68. Wardhana Datau EA Sultana A Mandang VVV Jim E The efficacy of Bacillus Calmette-Guerin vaccinations for the prevention of acute upper respiratory tract infection in the elderly Acta Med Indones 2011 43 3 185 190 21979284
Wardhana, Datau EA, Sultana A, Mandang VVV, Jim E. The efficacy of Bacillus Calmette-Guerin vaccinations for the prevention of acute upper respiratory tract infection in the elderly. Acta Med Indones. 2011;43(3):185–190.21979284
69. Ciabattini A Olivieri R Lazzeri E Medaglini D Role of the microbiota in the modulation of vaccine immune responses Front Microbiol 2019 10 1305 10.3389/fmicb.2019.01305 31333592
Ciabattini A, Olivieri R, Lazzeri E, Medaglini D. Role of the Microbiota in the Modulation of Vaccine Immune Responses. Front Microbiol. 2019;10:1305.31333592
70. Ng SC Peng Y Zhang L Mok CK Zhao S Li A Ching JY Liu Y Yan S Chan DLS Zhu J Chen C Fung AC Wong KKY Hui DSC Chan FKL Tun HM Gut microbiota composition is associated with SARSCoV-2 vaccine immunogenicity and adverse events Gut 2021 71 6 1106 1116 10.1136/gutjnl-2021-326563
Ng SC, Peng Y, Zhang L, Mok CK, Zhao S, Li A, Ching JY, Liu Y, Yan S, Chan DLS, Zhu J, Chen C, Fung AC, Wong KK, Hui DS, Chan FK, Tun HM. Gut microbiota composition is associated with SARSCoV-2 vaccine immunogenicity and adverse events. Gut. 2022;71(6):1106–1116. https://gut.bmj.com/content/71/6/1106
71. Pean N Le AL Brial Dominant gut Prevotella copri in gastrectomized non-obese diabetic Goto-Kakizaki rats improves glucose homeostasis through enhanced FXR signalling Diabetologia 2020 63 6 1223 1235 10.1007/s00125-020-05122-7 32173762
Péan N, Lay AL, Brial F, Wasserscheid J, Rouch C, Vincent M, Myridakis A, Hedjazi L, Dumas ME, Grundberg E, Lathrop M, Magnan C, Dewar K, Gauguier D. Dominant gut Prevotella copri in gastrectomized non-obese diabetic Goto-Kakizaki rats improves glucose homeostasis through enhanced FXR signalling. Diabetologia. 2020;63(6):1223-35.32173762
72. Sakon H Nagai F Morotomi M Sutterella parvirubra sp. nov. and Megamonas funiformis sp. nov., isolated from human faeces Int J Syst Evol Microbiol 2008 58 pt4 970 975 10.1099/ijs.0.65456-0 18398204
Sakon H, Nagai F, Morotomi M et al. Sutterella parvirubra sp. nov. and Megamonas funiformis sp. nov., isolated from human faeces. Int J Syst Evol Microbiol. 2008;58(pt4):970–5.18398204
73. Goncalves JIB Borges TJ deSouza APD Microbiota and response to vaccines against respiratory virus Front Immunol 2022 13 889945 10.3389/fimmu.2022.889945 35603203
Goncalves JIB, Borges TJ, deSouza APD. Microbiota and Response to vaccines against respiratory virus. Frontiers in immunology. 2022;13:889945.35603203
74. Blacher E Levy M Tatirovsky E Elinav E Microbiome-modulated metabolites at the interface of host immunity J Immunol 2017 198 2 572 580 10.4049/jimmunol.1601247 28069752
Blacher E, Levy M, Tatirovsky E, Elinav E. Microbiome-Modulated Metabolites at the Interface of Host Immunity. J Immunol. 2017;198(2):572–80. 10.4049/jimmunol.160124728069752
75. Kim CH Control of lymphocyte functions by gut microbiota-derived short-chain fatty acids Cell Mol Immunol 2021 18 5 1161 1171 10.1038/s41423-020-00625-0 33850311
Kim CH. Control of Lymphocyte Functions by Gut Microbiota-Derived Short-Chain Fatty Acids. Cell Mol Immunol. 2021;18(5):1161–71. 10.1038/s41423-020-00625-033850311
76. Su D Nie Y Zhu A Chen Z Wu P Zhang L Luo M Sun Q Cai L Lai Y Xiao Z Duan Z Zheng S Wu G Hu R Tsukamoto H Lugea A Liu Z Pandol S Han YP Vitamin D signaling through induction of paneth cell defensins maintains gut microbiota and improves metabolic disorders and hepatic steatosis in animal models Front Physiol 2016 7 498 10.3389/fphys.2016.00498 27895587
Su D, Nie Y, Zhu A, Chen Z, Wu P, Zhang L, Luo M, Sun Q, Cai L, Lai Y, Xiao Z, Duan Z, Zheng S, Wu G, Hu R, Tsukamoto H, Lugea A, Liu Z, Pandol SJ and Han YP. Vitamin D signaling through Induction of Paneth Cell Defensins maintains Gut Microbiota and Improves Metabolic Disorders and hepatic Steatosis in Animal Models. Front Physiol. 2016;7:498. 10.3389/fphys.2016.00498.27895587
77. Gutierrez S Svahn SL Johansson ME Effects of omega-3 fatty acids on immune cells Int J Mol Sci 2019 20 20 5028 10.3390/ijms20205028 31614433
Gutierrez S, Svahn SL, Johansson ME. Effects of Omega-3 Fatty Acids on Immune Cells. Int J Mol Sci. 2019;20(20):5028.31614433
78. Galbraith MD Kinning KT Sullivan KD Araya P Smith KP Granrath RE Shaw JR Baxter R Specialized interferon action in COVID-19 Immunol Inflamm 2022 119 11 e2116730119 10.1073/pnas.2116730119
Galbraith MD, Kinning KT, Sullivan KD, Araya P, Smith KP, Granrath RE, Shaw JR, Baxter R, Jordan KR, Russell S, Dzieciatkowska M, Reisz JA, Gamboni F, Cendali F, Ghosh T, Guo K, Wilson CC, Santiago ML, Monte AA, Bennett TD, Hansen KC, Hsieh EWY, D'Alessandro A, Espinosa JM. Specialized interferon action in COVID-19. Proc Natl Acad Sci USA. 2022;119(11):e2116730119. 10.1073/pnas.2116730119
79. Lokugamage KG, Hage A, de Vries M, Valero-Jimenez AM, Schindewolf C, Dittmann M, Rajsbaum R, Menachery VD. Type I interferon susceptibility distinguishes SARS-CoV-2 from SARS-CoV. Journal of Virology. 2020;94(23). 10.1128/jvi.01410-20
80. Van de Veerdonk FL Giamarellos-Bourboulis E Pickkers P Derde L Leavis H A guide to immunotherapy for COVID-19 Nat Med 2022 28 39 50 10.1038/s41591-021-01643-9 35064248
Van de Veerdonk FL, Giamarellos-Bourboulis E, Pickkers P, Derde L, Leavis H, van Crevel R, Engel JJ, Wiersinga WJ, Vlaar APJ, Shankar-Hari M, van der Poll T, Bonten M, Angus DC, van der Meer JWM, Netea MG. A guide to immunotherapy for COVID-19. Nature Medicine. 2022;28:39-50.35064248
81. Yamamoto S Saito M Tamura A Prawisuda D Mizutani T Yotsuyanagi H (2021) The human microbiome and COVID-19: a systematic review PLoS ONE 2021 16 6 e0253293 10.1371/journal.pone.0253293 34161373
Yamamoto S, Saito M, Tamura A, Prawisuda D, Mizutani T, Yotsuyanagi H (2021) The human microbiome and COVID-19: A systematic review. PLoS One. 2021;16(6):e0253293. 10.1371/journal.pone.0253293.34161373
82. Becattini S Taur Y Pamer EG Antibiotic-induced changes in the intestinal microbiota and disease Trends Mol Med 2016 22 458 478 10.1016/j.molmed.2016.04.003 27178527
Becattini S, Taur Y, Pamer EG. Antibiotic-induced Changes in the intestinal Microbiota and Disease. Trends Mol Med. 2016; 22(6):458–478.27178527
83. Negatu DA, Gengenbacher M, Dartois V, Dick T. Indole propionic acid, an unusual antibiotic produced by the gut microbiota, with anti-inflammatory and antioxidant properties. Front Microbiol. 2020;11. 10.3389/fmicb.2020.575586
84. Koneru G Batiha GEB Algammal AM Mabrok M Magdy S Sayed S Elmaged MEA Elnemr R Saad MM Ellah NHA Hosni A Muhammad K Hetta HF BCG vaccine induced Trained Immiunity and COVID-19: protective or bystander? Infect Drug Resist 2021 14 1169 1184 10.2147/IDR.S300162 33790587
Koneru G, Batiha GES, Algammal AM, Mabrok M, Magdy S, Sayed S, AbuElmaged ME, Elnemr R, Saad MM, Ellah NHA, Hosni A, Muhammad K, Hetta HF. BCG vaccine induced Trained Immiunity and COVID-19: Protective or Bystander? Infect Drug Resist. 2021;14:1169-1184. 10.2147/IDR.S300162.33790587
85. Kumar PN Padmapriyadarsini C Rajamanickam A Bhavani PK Nancy A BCG vaccination induces enhanced frequencies of dendritic cells and altered plasma levels of type I and type III interferons in elderly individuals Int J Infect Dis 2021 110 98 104 10.1016/j.ijid.2021.07.041 34302964
 Kumar PN, Padmapriyadarsini C, Rajamanickam A, Bhavani PK, Nancy A, Jeyadeepa B, Selvaraj N, Ashokan D, Renji RM, Venkataramani V, Tripathy S, Babu S. BCG vaccination induces enhanced frequencies of dendritic cells and altered plasma levels of type I and type III interferons in elderly individuals. Int J Infect Dis. 2021;110:98–104.34302964
86. Vyas U Ranganathan N Probiotics, prebiotics, and synbiotics: gut and beyond Gastroenterol Res Pract 2012 2012 872716 10.1155/2012/872716 23049548
Vyas U, Ranganathan N. Probiotics, prebiotics, and synbiotics: gut and beyond. Gastroenterol Res Pract. 2012;2012: 872716.23049548
87. Hemarajata P Versalovic J Effects of probiotics on gut microbiota: mechanisms of intestinal immunomodulation and neuromodulation Therap Adv Gastroenterol 2013 6 1 39 51 10.1177/1756283X12459294 23320049
Hemarajata P, Versalovic J. Effects of probiotics on gut microbiota: mechanisms of intestinal immunomodulation and neuromodulation. Therap Adv Gastroenterol. 2013;6(1):39–51.23320049
88. Minato T Nirasawa S Sato T Yamaguchi T Hoshizaki M Inagaki T Nakahara K Yoshihashi T Ozawa R Yokota S B38-CAP is a bacteria-derived ACE2-like enzyme that suppresses hypertension and cardiac dysfunction Nat Commun 2020 11 1058 10.1038/s41467-020-14867-z 32103002
 Minato T, Nirasawa S, Sato T, Yamaguchi T, Hoshizaki M, Inagaki T, Nakahara K, Yoshihashi T, Ozawa R, Yokota S, Natsui M, Koyota S, Yoshiya T, Yoshizawa-Kumagaye K, Motoyama S, Gotoh T, Nakaoka Y, Penninger JM, Watanabe H, Imai Y, Takahashi S, Kuba K. B38-CAP is a bacteria-derived ACE2-like enzyme that suppresses hypertension and cardiac dysfunction. Nat Commun. 2020;11:1058.32103002
89. Wang B Zhang L Wang Y Dai T Qin Z Zhou F Zhang L Alteration of microbiota of patients with COVID-19: potential mechanism and therapeutics Signal Transduct Ther 2022 7 143 10.1038/s41392-022-00986-0
Wang B, Zhang L, Wang Y, Dai T, Qin Z, Zhou F, Zhang L. Alteration of microbiota of patients with COVID-19: potential mechanism and therapeutics. Signal Transduction and Therapy. 2022;7:143.
90. de Oliveira GLV Oliveira CNS Pinzan CF de Salis LVV Cardoso CRB Microbiota modulation of the gut-lung axis in COVID-19 Front Immunol 2021 12 635471 10.3389/fimmu.2021.635471 33717181
de Oliveira GLV, Oliveira CNS, Pinzan CF, de Salis LVV, Cardoso CRB. Microbiota Modulation of the Gut-Lung Axis in COVID-19. Front Immunol. 2021; 12:635471.33717181
91. Di Ciaula A Stella A Bonfrate L Wang DQH Portincasa P Gut microbiota between environment and genetic background in familial mediterranean fever (FMF) Genes (Basel) 2010 11 9 1041 10.3390/genes11091041
Di Ciaula A, Stella A, Bonfrate L, Wang DQH, Portincasa P. Gut Microbiota between Environment and Genetic Background in Familial Mediterranean Fever (FMF). Genes (Basel). 2020;11(9):1041.
92. Guillemard E Tanguy J Flavigny A de la Motte S Schrezenmeir J Effects of consumption of a fermented dairy product containing the Probiotic lactobacillus casei dn-114001 on common respiratory and gastrointestinal infections in shift workers in a randomized controlled trial J Am Coll Nutr 2010 29 5 455 468 10.1080/07315724.2010.10719882 21504972
Guillemard E, Tanguy J, Flavigny AL, de la Motte S, and Schrezenmeir J. Effects of consumption of a Fermented Dairy Product Containing the Probiotic Lactobacillus casei DN-114001 on common Respiratory and Gastrointestinal Infections in Shift Workers in a Randomized Controlled Trial. J Am Coll Nutr. 2010;29(5):455–68.21504972
93. Szajewska H Kołodziej M Gieruszczak-Białek D Skórka A Ruszczyński M Shamir R Systematic review with meta-analysis: Lactobacillus rhamnosus GG for treating acute gastroenteritis in children—a 2019 update Aliment Pharmacol Ther 2019 49 11 1376 1384 10.1111/apt.15267 31025399
Szajewska H, Kołodziej M, Gieruszczak-Białek D, Skórka A, Ruszczyński M, Shamir R. Systematic review with meta-analysis: Lactobacillus rhamnosus GG for treating acute gastroenteritis in children - a 2019 update. Aliment Pharmacol Ther. 2019;49(11):1376–1384.31025399
94. Mak JWY Chan FKL Ng SC Probiotics and COVID-19: one size does not fit all Lancet Gastroenterol Hepatol 2020 5 7 644 645 10.1016/S2468-1253(20)30122-9 32339473
 Mak JWY, Chan FKL, Ng SC. Probiotics and COVID-19: One size does not fit all. Lancet Gastroenterol Hepatol. 2020;5(7):644–645.32339473
95. Kaushal A mRNA Technology a promising strategy for rapid response applications against the emerging infectious diseases Acta Sci Microbiol (2581–3226) 2021 4 3 199 212 10.31080/ASMI.2021.04.0797
Kaushal A. mRNA Technology a promising strategy for rapid response applications against the emerging infectious diseases. Acta Scientific Microbiology (2581-3226). 2021;4(3):199–212.
